WO1994019363A1 - Process for preparing phosphorothioate oligonucleotides - Google Patents
Process for preparing phosphorothioate oligonucleotides Download PDFInfo
- Publication number
- WO1994019363A1 WO1994019363A1 PCT/US1993/001574 US9301574W WO9419363A1 WO 1994019363 A1 WO1994019363 A1 WO 1994019363A1 US 9301574 W US9301574 W US 9301574W WO 9419363 A1 WO9419363 A1 WO 9419363A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkaryl
- aryl
- phosphorothioate
- compound
- nucleoside
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 93
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 title claims abstract description 85
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- -1 alkyl phosphorothioate diester salt Chemical class 0.000 claims abstract description 77
- 239000002777 nucleoside Substances 0.000 claims abstract description 59
- 125000003118 aryl group Chemical group 0.000 claims abstract description 53
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 41
- 239000002773 nucleotide Substances 0.000 claims abstract description 41
- 230000000903 blocking effect Effects 0.000 claims abstract description 39
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 239000000543 intermediate Substances 0.000 claims abstract description 30
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 15
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 77
- 230000008569 process Effects 0.000 claims description 36
- WQYSXVGEZYESBR-UHFFFAOYSA-N thiophosphoryl chloride Chemical compound ClP(Cl)(Cl)=S WQYSXVGEZYESBR-UHFFFAOYSA-N 0.000 claims description 21
- 150000001502 aryl halides Chemical class 0.000 claims description 16
- 239000007806 chemical reaction intermediate Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 125000003835 nucleoside group Chemical group 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 10
- HRBGUGQWTMBDTR-UHFFFAOYSA-N 2,3,4-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC=C(S(Cl)(=O)=O)C(C(C)C)=C1C(C)C HRBGUGQWTMBDTR-UHFFFAOYSA-N 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 5
- 239000012011 nucleophilic catalyst Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 229910018894 PSCl3 Inorganic materials 0.000 claims 7
- IRSVDHPYXFLLDS-UHFFFAOYSA-N 2,4-dichloro-1-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1Cl IRSVDHPYXFLLDS-UHFFFAOYSA-N 0.000 claims 2
- 125000006286 dichlorobenzyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 76
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 68
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 35
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 34
- 239000000203 mixture Substances 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 238000004679 31P NMR spectroscopy Methods 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 239000012043 crude product Substances 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- 239000006260 foam Substances 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- 230000007062 hydrolysis Effects 0.000 description 12
- 238000006460 hydrolysis reaction Methods 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 238000007068 beta-elimination reaction Methods 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical group CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000004185 ester group Chemical group 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 150000003973 alkyl amines Chemical group 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 150000003536 tetrazoles Chemical class 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- ZSPXTTVUJDSRNJ-UHFFFAOYSA-N (2,4-dichlorophenyl)methanethiol Chemical compound SCC1=CC=C(Cl)C=C1Cl ZSPXTTVUJDSRNJ-UHFFFAOYSA-N 0.000 description 3
- GKQXPTHQTXCXEV-UHFFFAOYSA-N (4-chlorophenyl)methanethiol Chemical group SCC1=CC=C(Cl)C=C1 GKQXPTHQTXCXEV-UHFFFAOYSA-N 0.000 description 3
- UBTJZUKVKGZHAD-JCYYIGJDSA-N 1-[(2r,4r,5r)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)(C=1C=CC=CC=1)OC[C@@H]1[C@H](O)C[C@H](N2C(NC(=O)C(C)=C2)=O)O1 UBTJZUKVKGZHAD-JCYYIGJDSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- WOFDVDFSGLBFAC-UHFFFAOYSA-N lactonitrile Chemical compound CC(O)C#N WOFDVDFSGLBFAC-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- PCKIYZZZOHQHIE-UHFFFAOYSA-N triethylazanium thiophosphate Chemical compound [O-]P([O-])([O-])=S.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC PCKIYZZZOHQHIE-UHFFFAOYSA-N 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- ANPWLBTUUNFQIO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(N(C(C)C)C(C)C)OCC1=CC=CC=C1 ANPWLBTUUNFQIO-UHFFFAOYSA-N 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- DWYIFWLWZXIIBQ-UHFFFAOYSA-N 2,2-dichloro-3-dihydroxyphosphinothioyloxypropanenitrile Chemical compound OP(O)(=S)OCC(Cl)(Cl)C#N DWYIFWLWZXIIBQ-UHFFFAOYSA-N 0.000 description 1
- JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 1
- LVAHJZMZVFBIAU-RBZQAINGSA-N 2-amino-9-[(2r,4s,5r)-5-(hydroxymethyl)-4-trityloxyoxolan-2-yl]-3h-purin-6-one Chemical compound O([C@H]1C[C@@H](O[C@@H]1CO)N1C=2N=C(NC(=O)C=2N=C1)N)C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LVAHJZMZVFBIAU-RBZQAINGSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical group CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- NKIKZNIGHFRCRG-UHFFFAOYSA-N 3-dihydroxyphosphinothioyloxypropanenitrile Chemical compound OP(O)(=S)OCCC#N NKIKZNIGHFRCRG-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GIJFGAPVRJPBQE-VCQOIINCSA-N C(C1=CC=CC=C1)(=O)NC=1C=2N=CN([C@]3(C[C@H](O)[C@@H](COOC(C)(C)C)O3)[SiH](C3=CC=CC=C3)C3=CC=CC=C3)C2N=CN1 Chemical compound C(C1=CC=CC=C1)(=O)NC=1C=2N=CN([C@]3(C[C@H](O)[C@@H](COOC(C)(C)C)O3)[SiH](C3=CC=CC=C3)C3=CC=CC=C3)C2N=CN1 GIJFGAPVRJPBQE-VCQOIINCSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GABQKHQNXWNJJJ-UHFFFAOYSA-N diphenylcarbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)C1=CC=CC=C1 GABQKHQNXWNJJJ-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005731 phosphitylation reaction Methods 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1653—Esters of thiophosphoric acids with arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Definitions
- This application is directed to a process for preparing phosphorothioate oligonucleotides and to intermediates used in that process.
- Nucleoside precursors are phosphitylated with S-(alkaryl or aryl) alkyl phosphorothioate diester salts and then reacted in solution phase to build phosphorothioate oligonucleotides.
- Antisense methodology is the complementary hybridization of relatively short oligonucleotides to single-stranded RNA or single-stranded DNA such that the normal, essential functions of these intracellular nucleic acids are disrupted.
- Hybridization involves sequence specific hydrogen bonding via Watson-Crick base pairs of the heterocyclic bases of oligo nucleotides to RNA or DNA. Such base pairs are said to be complementary to one another.
- Raton, Fl (1989) are thought to include at least two types.
- the first is hybridization arrest. This denotes a terminating event in which an oligonucleotide inhibitor binds to the target nucleic acid and thus prevents, by simple steric hindrance, the binding of essential proteins, most often ribosomes, to the nucleic acid.
- Methyl phosphonate oligonucleotides such as disclosed by Miller, P.S. and Ts'O, P.O. P. (1987) Anti-Cancer
- Drug Design 2:117-128, and ⁇ -anomer oligonucleotides are the two most extensively studied antisense agents that are thought to disrupt nucleic acid function by hybridization arrest.
- the relative ability of an oligonucleotide to bind to complementary nucleic acids may be compared by determining the melting temperature of a particular hybridization complex.
- the melting temperature (T m ) a characteristic physical property of double helixes, denotes the temperature in degrees centigrade at which 50% helical (hybridized) versus coil (unhybridized) forms are present.
- T m is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking, which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity).
- a second type of terminating event for antisense oligonucleotides involves the enzymatic cleavage of the targeted RNA by intracellular RNase H.
- the mechanism of RNase H cleavages requires the hybridization of a 2'-deoxyribo- furanosyl oligonucleotide to a targeted RNA.
- the resulting DNA-RNA duplex activates the RNase H enzyme.
- the activated enzyme cleaves the RNA strand. Cleavage of the RNA strand destroys the normal function of the RNA.
- Phosphorothioate oligonucleotides are one prominent example of antisense agents that operate by this type of antisense terminating event.
- the current method of choice for the preparation of phosphorothioate oligonucleotides is via solid-phase synthesis wherein an oligonucleotide is prepared on a polymer support.
- Solid-phase synthesis relies on sequential addition of nucleotides to one end of a growing oligonucleotide.
- a first nucleoside is attached to an appropriate glass bead support and nucleotide phosphoramidites are added stepwise to elongate the growing oligonucleotide.
- the nucleotide phosphoramidites are reacted with the growing oligonucleotide using the principles of a "fluidized bed" for mixing of the reagents.
- the known silica supports suitable for anchoring the oligonucleotide are very fragile and thus can not be exposed to aggressive mixing.
- Brill, W. K.-D., Tang, J.-Y., Ma, Y.-Y. and Caruthers, M.H. (1989) J. Am . Chem . Soc , 111: 2321 disclosed a procedure wherein an aryl mercaptan is substituted for the nucleotide phosphoramidite to prepare phosphorodithioate oligonucleotides on glass supports.
- the oligonucleotide is synthesized as an elongating strand.
- the number of individual strands that can be anchored to a unit surface area of the support is limited.
- the activated nucleotides that are added to the growing oligonucleotide are relatively expensive and must be used in stoichiometric excess.
- Solution-phase synthetic oligonucleotide techniques should be useful for large scale preparation.
- One such solution phase preparation utilizes phosphorus triesters.
- the triester oligonucleotide approach can be utilized to prepare thymidine dinucleoside and thymidine dinucleotide phosphorodithioates.
- the phosphorylated thymidine nucleoside intermediates utilized in this approach were obtained by treatment of commercially available 5'-O-dimethoxy- tritylthymidine-3'-[( ⁇ -cyanoethyl)-N,N-diisopropyl]-phosphoramidite first with either 4-chloro or 2,4-dichlorobenzyl- mercaptan and tetrazole and then a saturated sulfur solution. The resulting phosphorodithioate nucleotide was then reacted via the triester synthesis method with a further thymidine nucleoside having a free 5'-hydroxyl.
- a still further object is to provide intermediates for preparing phosphorothioate oligonucleotides.
- these processes include the steps of (a) reacting thiophosphoryl chloride (PSCl 3 ) with an alkaryl halide or an aryl halide to form a first reaction intermediate and then, (b) reacting the first reaction intermediate with a nucleoside having a 3'-hydroxyl moiety, a nucleotide having a 3'-hydroxyl moiety, or an oligonucleotide having a 3'-hydroxyl moiety to form a second reaction intermediate selected from a nucleoside 3'-S-(alkaryl or aryl) phosphorothioate, a nucleotide 3' -S-(alkaryl or aryl) phosphorothioate or an oligonucleotide 3'-S-(alkaryl or aryl) phosphorothioate.
- PSCl 3 thiophosphoryl chloride
- the second reaction intermediate then is, (c) reacted with a nucleoside having a free 5'-hydroxyl moiety, a nucleotide having a free 5'-hydroxyl moiety or an oligonucleotide having a free 5'-hydroxyl moiety in the presence of an activating agent to form an ester linkage between a S-(alkaryl or aryl) phosphorothioate moiety of said second reaction intermediate and said 5'-hydroxyl moiety.
- these processes include the further steps of hydrolyzing the PSCl 3 prior to reacting the PSCl 3 with the alkaryl or aryl halide and reacting the hydrolyzed PSCl 3 with the alkaryl or aryl halide.
- Even more preferred processes include the further steps of reacting the PSCl 3 with an alkyl alcohol prior to hydrolysis to form an alkoxy intermediate and then hydrolyzing the alkoxy intermediate prior to reacting the hydrolyzed alkoxy intermediate with the alkaryl or aryl halide.
- step (c) of the above-described process is reacted one or more times with one of a further nucleoside 3'-S-(alkaryl or aryl) phosphorothioate, nucleotide 3 '-S- (alkaryl or aryl) phos phorothioate or oligonucleotide 3'-S-(alkaryl or aryl) phosphorothioate.
- processes for the preparation of phosphorothioate internucleoside linkages include phosphitylating two 5'-blocked nucleosides with an S-(alkaryl or aryl) alkyl phosphorothioate diester salt followed by deblocking the 5'-blocking group from one of the phosphitylated nucleosides and dealkylating the other of the phosphitylated nucleosides.
- the dealkylated nucleoside is then reacted with the deblocked nucleoside to form a dinucleoside having an S-(alkaryl or aryl) phosphorothioate internucleoside linkage.
- the S-(alkaryl or aryl) bond of the S-(alkaryl or aryl) phosphorothioate internucleo- side linkage is cleaved to yield a dinucleoside having a phosphorothioate internucleoside linkage.
- 2,4-Dichlorobenzyl is preferred as the alkaryl or aryl moiety of the S-(alkaryl or aryl) alkyl phosphorothioate diester salt and ⁇ -cyanoethyl is preferred as the alkyl moiety of S-(alkaryl or aryl) alkyl phosphorothioate diester salt.
- X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide
- Y is H, a second blocking group, a nucleoside, a nucleotide or an oligonucleotide
- R is an alkaryl or aryl group; n is an integer greater than 0; and
- Bx is a heterocyclic base.
- X is H, a first blocking group, nucleoside, a nucleotide or an oligonucleotide
- Y is H, a second blocking group, nucleoside, a nucleotide or an oligonucleotide
- Z is X or P-S-R
- R is an alkaryl or aryl group
- n is an integer greater than 0;
- Bx is a heterocyclic base.
- oligonucleotide in a first instance refers to a polynucleotide formed from a plurality of joined nucleotide units. The nucleotides are joined via phosphorothioate inter-nucleo- side linkages. The nucleotides are formed from naturally occurring bases and pentofuranosyl sugar groups. The term “oligonucleotide” thus effectively includes naturally occurring species or synthetic species formed from naturally occurring subunits.
- Oligonucleotides according to the invention also can include modified subunits. Representative modifications include modification of a heterocyclic base portion of a nucleotide or a sugar portion of a nucleotide. Exemplary modifications are disclosed in the following United States Patent Applications: Serial No. 463,358, filed January 11, 1990, entitled Compositions And Methods For Detecting And Modulating RNA Activity; Serial No. 566,977, filed August 13, 1990, entitled Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression; Serial No. 558,663, filed July 27, 1990, entitled Novel Polyamine Conjugated Oligonucleotides; Serial No.
- oligonucleotide thus refers to structures that include modified portions, be they modified sugar moieties or modified base moieties, that function similarly to natural bases and natural sugars.
- Representative modified bases include deaza or aza purines and pyrimidines used in place of natural purine and pyrimidine bases; pyrimidines having substituent groups at the 5 or 6 position; purines having altered or replacement substituent groups at the 2 , 6 or 8 positions.
- Representative modified sugars include carbocyclic or acyclic sugars, sugars having substituent groups at their 2' position, and sugars having substituents in place of one or more hydrogen atoms of the sugar. Other altered base moieties and altered sugar moieties are disclosed in United States Patent 3,687,808 and PCT application PCT/US89/02323.
- Altered base moieties or altered sugar moieties also include other modifications consistent with the spirit of this invention.
- Such oligonucleotides are best described as moieties that are structurally distinguishable from yet functionally interchangeable with naturally occurring or synthetic wild type oligonucleotides. All such oligonucleotides are comprehended by this invention so long as they function effectively to mimic the structure of a desired RNA or DNA strand.
- the phosphorothioate oligonucleotides of the invention preferably comprise from about 10 to about 30 subunits. It is more preferred that such oligonucleotides comprise from about 15 to about 25 subunits.
- a subunit is a base and sugar combination suitably bound to adjacent subunits through a phosphorothioate linkage.
- building blocks in assembling phosphorothioate oligonucleotides, even smaller assemblies are preferred.
- the smallest assembly is a phosphorothioate nucleotide having S-(alkaryl or aryl) and alkyl ester groups.
- the smallest dinucleoside assembly is two nucleosides linked by a protected phosphorothioate linkage.
- phosphorothioate oligonucleotides having tens or even hundreds of individual nucleotide subunits can be prepared utilizing the processes and intermediates of this invention. Such very large phosphorothioate oligonucleotides can be assembled from smaller oligonucleotide intermediates that, in turn, would be assembled from even smaller intermediates. Thus, phosphorothioate oligonucleotides and phosphorothioate oligonucleotide intermediates of the invention contain one or more subunits.
- the phosphorothioate oligonucleotides of the invention can be used in diagnostics, therapeutics and as research reagents and kits. They can be used in pharmaceutical compositions by including a suitable pharmaceutically accept able diluent or carrier. They further can be used for treating organisms having a disease characterized by the undesired production of a protein.
- the organism should be contacted with a phosphorothioate oligonucleotide having a sequence that is capable of specifically hybridizing with a strand of nucleic acid coding for the undesirable protein. Treatments of this type can be practiced one a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms.
- Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular control is susceptible to therapeutic and/or prophylactic treatment in accordance with the invention. Seemingly diverse organisms such as bacteria, yeast, protozoa, algae, all plants and all higher animal forms, including warm-blooded animals, can be treated. Further, since each cell of multicellular eukaryotes can be treated since they include both DNA-RNA transcription and RNA-protein translation as integral parts of their cellular activity. Furthermore, many of the organelles (e . g . , mitochondria and chloroplasts) of eukaryotic cells also include transcription and translation mechanisms.
- organelles e . g . , mitochondria and chloroplasts
- single cells, cellular populations or organelles can also be included within the definition of organisms that can be treated with therapeutic or diagnostic phosphorothioate oligonucleotides.
- therapeutics is meant to include the eradication of a disease state, by killing an organism or by control of erratic or harmful cellular growth or expression.
- thiophosphoryl chloride (PSCl 3 ; structure 1) is treated with an alkyl alcohol such as cyanoethanol (structure 2) in the presence of a suitable HCl scavenger to yield a mixture of mono, di and tri alkylated phosphorothioate species (mixture 1; structures 3, 4 and 5).
- C 1 to C 10 alkyl alcohols are preferred.
- alkyl alcohols comprising a substituent that can be activated to facilitate removal of the alkyl group.
- cyanoethanol contains a cyanoethyl moiety that can be eliminated via a controlled ⁇ -elimination reaction.
- alkyl alcohols include electron withdrawing groups positioned on the alkyl chain such that reaction with PSCl 3 results in an acidic proton located on the carbon atom ⁇ to the phosphorus atom.
- Representative electron withdrawing groups include methyl groups [Daub, G.W. and van Tamelen, E.E. (1976) J. Am . Chem . Soc. 98:3526.], 2,2,2-trichloroethyl groups [Letsinger, R.L. and Lunsford, W.B. (1976) J. Am . Chem .
- HCl scavenger 2,6-lutidine, which facilitates the reactivity of the alkyl alcohol with the chloro substituents of the PSCl 3 .
- Other useful HCl scavengers include diisopropylethylamine, 2-methylpyridine or other hindered tertiary amines.
- one of the alkyl esters of structure 5 should be cleaved.
- cyanoethyl esters can be cleaved via a ⁇ -elimina- tion reaction to yield a further mixture (mixture 2) containing ⁇ -cyanoethyl phosphorothioate ester (structure 6) and di( ⁇ - cyanoethyl) phosphorothioate ester (structure 7).
- mixture 2 containing ⁇ -cyanoethyl phosphorothioate ester (structure 6) and di( ⁇ - cyanoethyl) phosphorothioate ester (structure 7).
- hydrolysis and cleavage are effected concurrently by treating mixture 1 with an aqueous tertiary alkylamine.
- Preferred tertiary alkylamines are trialkyl amines such as triethylamine and diisopropylethyl amine.
- the electron withdrawing effect of the cyano group is believed to result in abstraction by the tertiary alkyl amine of a cyanoethyl proton and elimination of the cyanoethyl ester.
- a 1:1 (volume:volume) mixture of 0.5 M triethylamine buffer in acetonitrile is preferred.
- Structures 3 and 4 can be hydrolyzed without cleavage of structure 5 by, for example, treating mixture 1 with an amine species that does not effect ⁇ -elimination. Unreacted structure 5 then can be removed from the hydrolysis product. It will be recognized, however, that the overall yields from such a procedure likely will be low.
- the phosphorothioate moieties that result upon ⁇ -elimination of a first cyanoethyl ester group of structures 4 or 5 or upon hydrolysis of a chloro group of structures 3 or 4 have a single anionic charge. The presence of this charge inhibits ⁇ -elimination of ⁇ -cyanoethyl ester groups. As a result, structure 5 is cleaved to form a di-( ⁇ - cyanoethyl) phosphorothioate diester (structure 6). Structure
- mixture 2 is then reacted with an alkaryl halide or an aryl halide (structure 8) such as a benzyl, substituted benzyl, phenyl or substituted phenyl halide. This results in the formation of an S-alkaryl or S-aryl ester, i.e.
- Concurrent treatment with a tertiary alkylamine results in ⁇ -elimination of one of the cyano-ethyl ester groups of the S-(alkaryl or aryl)-di-( ⁇ -cyanoethyl) phosphorothioate to provide an S-(alkaryl or aryl)- ⁇ -cyanoethyl phosphorothioate diester having structure 9.
- This S-(alkaryl or aryl) alkyl phosphorothioate diester salt has a single anionic charge and, thus, is inert to further ⁇ -elimination.
- Structure 9 preferably is a triethyl ammonium salt, a diisopropylethyl ammonium salt, or a mixture thereof.
- Representative compounds having structure 9 include S-(4- chlorobenzyl)- ⁇ -cyanoethyl phosphorothioate diester salt, S-
- (2,4-dichlorophenyl)- ⁇ -cyanoethyl phosphorothioate diester salt S-(2,4-dichlorophenyl)- ⁇ -cyanoethyl phosphorothioate diester salt and S-benzyl- ⁇ -cyanoethyl phosphorothioate diester salt.
- S-(2,4-dichlorobenzyl)- ⁇ -cyanoethyl phosphorothioate diester salt is preferred.
- a salt having structure 9 can be used to directly phosphitylate a 3'-hydroxy nucleoside (structure 10) to produce a nucleoside S-(aryl) alkyl phosphorothioate triester (structure 11).
- structure 10 a nucleoside S-(aryl) alkyl phosphorothioate triester
- Y a suitable blocking group
- Bx heterocyclic base
- thymidine (or uracil if RNA nucleosides are utilized) need only be blocked at the 5' hydroxyl position, while cytidine and adenosine preferably also are blocked on their heterocyclic bases utilizing benzyl blocking groups.
- Guanosine should be blocked at the 6-keto position of its heterocyclic base with a suitable keto blocking group including but not limited to diphenylcarbamate, isobutyryl (after first reacting with 1,2-glyoxal and including an additional isobutyryl group at the N2 position of the heterocyclic base in the manner of Matsuzaki, J., Kohno, K., Tahara, S., Sekine, M. and Hata, T.
- nucleosides having general structure 10 can be incorporated into phosphorothioate oligonucleotides utilizing the process of the invention. Suitable nucleosides are disclosed in the patents, patent applications, and/or papers noted above.
- the 5' hydroxyl blocking group Y can be selected from dimethoxytrityl (DMTr), methoxytrityl (MTr), trityl (Tr), tert- butyldimethylsilyl (TBDMSi), tert-butoxydiphenylsilyl (TBODPSi), dialkylphosphite, pivalylisobutyloxycarbonyl and other known hydroxyl blocking groups. Dimethoxytrityl and tert-butoxydiphenylsilyl groups are preferred.
- blocking group Y is selected to be base stable and acid labile.
- Deblocking of such groups usually can be effected with acids such as 3% trichloroacetic acid (3% TCA) or a Lewis acid such as ZnBr 2 or TiCl 4 . See, e . g. , Matteucci, M.D. and Caruthers, M.H. (1981) J . Am . Chem . Soc , 103:3185]
- acids such as 3% trichloroacetic acid (3% TCA) or a Lewis acid such as ZnBr 2 or TiCl 4 .
- nucleoside of structure 11 Since the nucleoside of structure 11 does not bear an anionic charge, treatment with an amine removes the remaining ⁇ -cyanoethyl ester group on the phosphorothioate moiety to yield structure 12. Treatment of structure 11 with acid removes the 5' hydroxyl blocking group and yields structure 13, i.e. a phosphorothioated nucleoside having a free 5' hydroxyl group.
- dimethoxytrityl blocking groups can be removed with either 3% trichloroacetic acid or ZnBr 2 .
- Reaction of structures 12 and 13 is conducted in the presence of an activating agent.
- activating agents are disclosed by Yau, E.K., Ma, Y.-X. and Caruthers, M.H. (1990) Tetrahedron Letters, 31:1953.
- a particularly preferred activating agent is triisopropylbenzenesulfonylchloride (TPSCl), which normally is used in the presence of a nucleophilic catalyst such as 1-methylimidazole.
- TPSCl triisopropylbenzenesulfonylchloride
- Dinucleotide structure 14 can be deblocked at its 3' terminal phosphorothioate to yield compounds of structure 15 and at its 5' terminal hydroxyl group to yield compounds of structure 16. Reaction of dinucleotide compounds having structures 15 and 16 in the presence of the activating agent will yield tetrameric oligonucleotides having structure 17, as shown in Scheme IV. Oligonucleotides having structure 17 can then be elongated using reactions analogous to those shown in Schemes II or III to effect the addition of nucleosides, phosphorothioate nucleotides, phosphorothioate dinucleotides or phosphorothioate oligonucleotides.
- Phosphodiester or other non-phosphorothioate nucleotides, dinucleotides or oligonucleotides can be added to the phosphorothioate oligonucleotide intermediates of this invention by reacting the non-phosphorothioate species with an activated phosphorothioate intermediate such as structure 12, structure 15, structure 17 or structure 22.
- an activated phosphorothioate intermediate such as structure 12, structure 15, structure 17 or structure 22.
- the non-phosphorothioate species should have a free 5' hydroxyl group that can form an ester linkage with the phosphorothioate intermediate or other like structure.
- non-phosphorothioate species at the 5' terminus of a phosphorothioate intermediate, the non-phosphorothioate species should be added as an activated species to a phosphorothioate intermediate such as structure 13, structure 16 or structure 20 having a free 5' hydroxyl group.
- the S-alkaryl or S-aryl blocking groups on the phosphorothioate linkages are removed.
- Deblocking of the S-alkaryl or S-aryl group preferably is effected utilizing thiophenolate in the manner described by Brill, W. K.-D., Nielsen, J. and Caruthers, M.H. (1991) J. Am . Chem . Soc , 113:3972.
- Other deblocking conditions using thiophenol are described by Brill, W. K.-D., Tang, J.-T., Ma, Y.-X. and Caruthers, M.H. (1989) J. Am . Chem . Soc , 111:2321.
- Y is a blocking group
- M is a metal salt
- Bx is a heterocyclic base
- TPSC1 is triisopropylbenzenesulfonylchloride
- Melm is methylimidazole
- TCA is trichloroacetic acid
- THF is tetrahydrofuran
- DMTr is dimethoxytrityl
- OCE is cyanoethoxy.
- X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide
- Y is H, a second blocking group, a nucleoside, a nucleotide or an oligonucleotide
- R is an alkaryl or aryl group
- n is an integer greater than 0
- Bx is a heterocyclic base.
- X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide
- Y is H, a second blocking group, a nucleoside, a nucleotide or an oligonucleotide
- Z is X or P-S-R
- R is an aryl group
- n is an integer greater than 0
- Bx is a heterocyclic base.
- heterocyclic base groups In each of these structures, heterocyclic base groups
- Bx of individual nucleosides or nucleotides can be the same or different.
- Bx preferably is a purin-9-yl or pyrimidin-1-yl base, more preferably adenine, guanine, cytosine, thymine, uracil, hypoxanthine, 2-aminoadenine or 5-methylcytosine.
- the syrupy product (9) (9.49 g) was obtained as a 9:1 mixture of the diisopropylethyl ammonium and triethyl ammonium salt forms, respectively. (42% yield based on PSCl 3 ) 31 P-NMR (CDCl 3 ; ppm) : 17.1.
- Crude compound 19 will be obtained from compound 18 by using a similar method to that described for the preparation of (12a).
- the DMT protecting group of compound 17 will be removed to yield crude compound 20 by using a similar method to that described for the preparation of (13a).
- Crude compound (19) and compound (20) will be reacted by using a similar method to that described for the preparation of (14a or 14b).
- the crude product will be purified by flash column chromatography on silica gel (75:23:2:0.7 CH 2 Cl 2 /aceton- e/MeOH/pyridine ⁇ 95:5:.7 CH 2 Cl 2 /MeOH/pyridine) to give (21) as a foam.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
Abstract
A process for preparing phosphorothioate oligonucleotides utilizes S-(alkaryl or aryl) phosphorothioate compounds as intermediates suitable for use in the solution phase. A dinucleotide is prepared from a nucleoside intermediate that has been phosphitylated with an S-(alkaryl or aryl) alkyl phosphorothioate diester salt. The alkyl ester group is removed and the resulting nucleotide diester is reacted with a further nucleoside having a free 5'-hydroxyl group. Nucleotide units are linked together to yield compounds of structure (I), where X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide; Y is H, a second and blocking group, a nucleoside, a nucleotide or an oligonucleotide; R is an alkaryl or aryl group; n is an integer greater than 0; and Bx is a heterocyclic base. Deblocking of the S-alkaryl or S-aryl moiety yields a phosphorothioate oligonucleotide.
Description
PROCESS FOR PREPARING PHOSPHOROTHIOATE OLIGONUCLEOTIDES
BACKGROUND OF THE INVENTION
This application is directed to a process for preparing phosphorothioate oligonucleotides and to intermediates used in that process. Nucleoside precursors are phosphitylated with S-(alkaryl or aryl) alkyl phosphorothioate diester salts and then reacted in solution phase to build phosphorothioate oligonucleotides.
It is well known that most of the bodily states in mammals including most disease states, are effected by proteins . Such proteins , either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man. Classical therapeutics has generally focused upon interactions with such proteins in an effort to moderate their disease causing or disease potentiating functions. Recently, however, antisense methodology has been introduced to moderate the actual production of such proteins by interactions with messenger RNA (mRNA) or other intracellular RNA's that direct protein synthesis or with DNA's that direct the production of RNA. It is a general object of such therapeutic approaches to interfere with or otherwise modulate the expression of genes associated with undesired protein formation.
Antisense methodology is the complementary hybridization of relatively short oligonucleotides to single-stranded RNA or single-stranded DNA such that the normal, essential functions of these intracellular nucleic acids are disrupted. Hybridization involves sequence specific hydrogen bonding via Watson-Crick base pairs of the heterocyclic bases of oligo
nucleotides to RNA or DNA. Such base pairs are said to be complementary to one another.
Events that provide for the disruption of the nucleic acid function, as discussed by Cohen in Oligonucleotides : Antisense Inhibitors of Gene Expression , CRC Press, Inc., Boca
Raton, Fl (1989), are thought to include at least two types.
The first is hybridization arrest. This denotes a terminating event in which an oligonucleotide inhibitor binds to the target nucleic acid and thus prevents, by simple steric hindrance, the binding of essential proteins, most often ribosomes, to the nucleic acid. Methyl phosphonate oligonucleotides such as disclosed by Miller, P.S. and Ts'O, P.O. P. (1987) Anti-Cancer
Drug Design , 2:117-128, and α-anomer oligonucleotides are the two most extensively studied antisense agents that are thought to disrupt nucleic acid function by hybridization arrest.
In determining the extent of hybridization arrest of an oligonucleotide, the relative ability of an oligonucleotide to bind to complementary nucleic acids may be compared by determining the melting temperature of a particular hybridization complex. The melting temperature (Tm), a characteristic physical property of double helixes, denotes the temperature in degrees centigrade at which 50% helical (hybridized) versus coil (unhybridized) forms are present. Tm is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking, which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity). Consequently, a reduction in UV absorption indicates a higher Tm, The higher the Tm, the greater the strength of the binding of the strands. Non- Watson-Crick base pairing, i.e. base mismatch, has a strong destabilizing effect seen as a decrease in Tm.
A second type of terminating event for antisense oligonucleotides involves the enzymatic cleavage of the targeted RNA by intracellular RNase H. The mechanism of RNase H cleavages requires the hybridization of a 2'-deoxyribo- furanosyl oligonucleotide to a targeted RNA. The resulting DNA-RNA duplex activates the RNase H enzyme. The activated
enzyme cleaves the RNA strand. Cleavage of the RNA strand destroys the normal function of the RNA. Phosphorothioate oligonucleotides are one prominent example of antisense agents that operate by this type of antisense terminating event.
The current method of choice for the preparation of phosphorothioate oligonucleotides is via solid-phase synthesis wherein an oligonucleotide is prepared on a polymer support. Solid-phase synthesis relies on sequential addition of nucleotides to one end of a growing oligonucleotide. Typically, a first nucleoside is attached to an appropriate glass bead support and nucleotide phosphoramidites are added stepwise to elongate the growing oligonucleotide. The nucleotide phosphoramidites are reacted with the growing oligonucleotide using the principles of a "fluidized bed" for mixing of the reagents. The known silica supports suitable for anchoring the oligonucleotide are very fragile and thus can not be exposed to aggressive mixing. Brill, W. K.-D., Tang, J.-Y., Ma, Y.-Y. and Caruthers, M.H. (1989) J. Am . Chem . Soc , 111: 2321 disclosed a procedure wherein an aryl mercaptan is substituted for the nucleotide phosphoramidite to prepare phosphorodithioate oligonucleotides on glass supports.
In these and other solid-phase procedures the oligonucleotide is synthesized as an elongating strand. However, the number of individual strands that can be anchored to a unit surface area of the support is limited. Also, the activated nucleotides that are added to the growing oligonucleotide are relatively expensive and must be used in stoichiometric excess.
While presently-utilized solid-phase syntheses are very useful for preparing small quantities of oligonucleotide, i.e., up to about 0.4 mole per synthetic run, they typically are not amenable to the preparation of the larger quantities of oligonucleotides necessary for biophysical studies, preclinical and clinical trials and commercial production. A general review of solid-phase verse solution-phase oligonucleotide synthesis is given in the background section of United States Patent 4,517,338, entitled Multiple Reactor
System And Method For Polynucleotide Synthesis, to Urdea, et al .
Solution-phase synthetic oligonucleotide techniques should be useful for large scale preparation. One such solution phase preparation utilizes phosphorus triesters. As I reported [Yau, E.K., Ma, Y.-S. and Caruthers (1990) Tetrahedron Letters , 31:1953], the triester oligonucleotide approach can be utilized to prepare thymidine dinucleoside and thymidine dinucleotide phosphorodithioates. The phosphorylated thymidine nucleoside intermediates utilized in this approach were obtained by treatment of commercially available 5'-O-dimethoxy- tritylthymidine-3'-[(β-cyanoethyl)-N,N-diisopropyl]-phosphoramidite first with either 4-chloro or 2,4-dichlorobenzyl- mercaptan and tetrazole and then a saturated sulfur solution. The resulting phosphorodithioate nucleotide was then reacted via the triester synthesis method with a further thymidine nucleoside having a free 5'-hydroxyl.
Brill, W.K.-D., Nielsen, J. and Caruthers, M.H. (1991) J . Am . Chem . Soc . , 113:3972, recently disclosed that treatment of a phosphoramidite such as N,N-diisopropyl phosphoramidite with a mercaptan such as 4-chloro or 2,4- dichlorobenzylmercaptan in the presence of tetrazole yields a derivative suitable for preparation of a phosphorodithioate as a major product and a derivative suitable for preparation of a phosphorothioate as a minor product. Substituting 4-chloro or 2,4-dichlorobenzylmercaptan for N,N-diisopropyl phosphoramidite therefore would be expected to result in low yields of phosphorothioate oligonucleotides.
Thus, although the utility of phosphorothioate oligonucleotides in antisense methodology has been recognized, the art suggests no large scale techniques for their preparation. Accordingly, there remains a long-felt need for such methods and for intermediates useful in such methods.
OBJECTS OF THE INVENTION
It is one object of this invention to provide new and improved oligonucleotide synthetic methods.
It is a further object to provide improved methods for the preparation of phosphorothioate oligonucleotides.
A still further object is to provide intermediates for preparing phosphorothioate oligonucleotides. BRIEF DESCRIPTION OF THE INVENTION
In accordance with this invention there are provided processes for the preparation of phosphorothioate oligonucleotides. In certain embodiments, these processes include the steps of (a) reacting thiophosphoryl chloride (PSCl3) with an alkaryl halide or an aryl halide to form a first reaction intermediate and then, (b) reacting the first reaction intermediate with a nucleoside having a 3'-hydroxyl moiety, a nucleotide having a 3'-hydroxyl moiety, or an oligonucleotide having a 3'-hydroxyl moiety to form a second reaction intermediate selected from a nucleoside 3'-S-(alkaryl or aryl) phosphorothioate, a nucleotide 3' -S-(alkaryl or aryl) phosphorothioate or an oligonucleotide 3'-S-(alkaryl or aryl) phosphorothioate. The second reaction intermediate then is, (c) reacted with a nucleoside having a free 5'-hydroxyl moiety, a nucleotide having a free 5'-hydroxyl moiety or an oligonucleotide having a free 5'-hydroxyl moiety in the presence of an activating agent to form an ester linkage between a S-(alkaryl or aryl) phosphorothioate moiety of said second reaction intermediate and said 5'-hydroxyl moiety.
Preferably these processes include the further steps of hydrolyzing the PSCl3 prior to reacting the PSCl3 with the alkaryl or aryl halide and reacting the hydrolyzed PSCl3 with the alkaryl or aryl halide. Even more preferred processes include the further steps of reacting the PSCl3 with an alkyl alcohol prior to hydrolysis to form an alkoxy intermediate and then hydrolyzing the alkoxy intermediate prior to reacting the hydrolyzed alkoxy intermediate with the alkaryl or aryl halide.
In preferred embodiments of the invention, the product of step (c) of the above-described process is reacted one or more times with one of a further nucleoside 3'-S-(alkaryl or aryl) phosphorothioate, nucleotide 3 '-S- (alkaryl or aryl) phos
phorothioate or oligonucleotide 3'-S-(alkaryl or aryl) phosphorothioate.
Further in accordance with this invention there are provided processes for the preparation of phosphorothioate internucleoside linkages. In certain embodiments, these processes include phosphitylating two 5'-blocked nucleosides with an S-(alkaryl or aryl) alkyl phosphorothioate diester salt followed by deblocking the 5'-blocking group from one of the phosphitylated nucleosides and dealkylating the other of the phosphitylated nucleosides. The dealkylated nucleoside is then reacted with the deblocked nucleoside to form a dinucleoside having an S-(alkaryl or aryl) phosphorothioate internucleoside linkage. In preferred embodiments, the S-(alkaryl or aryl) bond of the S-(alkaryl or aryl) phosphorothioate internucleo- side linkage is cleaved to yield a dinucleoside having a phosphorothioate internucleoside linkage. 2,4-Dichlorobenzyl is preferred as the alkaryl or aryl moiety of the S-(alkaryl or aryl) alkyl phosphorothioate diester salt and β-cyanoethyl is preferred as the alkyl moiety of S-(alkaryl or aryl) alkyl phosphorothioate diester salt.
Further in accordance with this invention are provided compounds of the structure:
wherein:
X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide;
Y is H, a second blocking group, a nucleoside, a nucleotide or an oligonucleotide;
R is an alkaryl or aryl group;
n is an integer greater than 0; and
Bx is a heterocyclic base.
Further in accordance with this invention are provided compounds of the structure:
wherein:
X is H, a first blocking group, nucleoside, a nucleotide or an oligonucleotide;
Y is H, a second blocking group, nucleoside, a nucleotide or an oligonucleotide;
Z is X or P-S-R
O-X;
R is an alkaryl or aryl group;
n is an integer greater than 0; and
Bx is a heterocyclic base.
DETAILED DESCRIPTION OF THE INVENTION
This invention provides new and improved processes for the preparation of phosphorothioate oligonucleotides and for intermediates useful in these processes. Utilizing these processes and intermediates, phosphorothioate oligonucleotides are prepared from a plurality of phosphorothioate nucleotide subunits. The nucleotide subunits may be "natural" or "syn- thetic" moieties. Thus, in the context of this invention, the
term "oligonucleotide" in a first instance refers to a polynucleotide formed from a plurality of joined nucleotide units. The nucleotides are joined via phosphorothioate inter-nucleo- side linkages. The nucleotides are formed from naturally occurring bases and pentofuranosyl sugar groups. The term "oligonucleotide" thus effectively includes naturally occurring species or synthetic species formed from naturally occurring subunits.
Oligonucleotides according to the invention also can include modified subunits. Representative modifications include modification of a heterocyclic base portion of a nucleotide or a sugar portion of a nucleotide. Exemplary modifications are disclosed in the following United States Patent Applications: Serial No. 463,358, filed January 11, 1990, entitled Compositions And Methods For Detecting And Modulating RNA Activity; Serial No. 566,977, filed August 13, 1990, entitled Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression; Serial No. 558,663, filed July 27, 1990, entitled Novel Polyamine Conjugated Oligonucleotides; Serial No. 558,806, filed July 27, 1991, entitled Nuclease Resistant Pyrimidine Modified Oligonucleotides That Detect And Modulate Gene Expression and Serial No. PCT/US91/00243, filed January 11, 1991, entitled Compositions and Methods For Detecting And Modulating RNA Activity. Each of these patent applications are assigned to the assignee of this invention. The disclosure of each is herein incorporated by reference.
The term oligonucleotide thus refers to structures that include modified portions, be they modified sugar moieties or modified base moieties, that function similarly to natural bases and natural sugars. Representative modified bases include deaza or aza purines and pyrimidines used in place of natural purine and pyrimidine bases; pyrimidines having substituent groups at the 5 or 6 position; purines having altered or replacement substituent groups at the 2 , 6 or 8 positions. Representative modified sugars include carbocyclic or acyclic sugars, sugars having substituent groups at their 2' position, and sugars having substituents in place of one or
more hydrogen atoms of the sugar. Other altered base moieties and altered sugar moieties are disclosed in United States Patent 3,687,808 and PCT application PCT/US89/02323.
Altered base moieties or altered sugar moieties also include other modifications consistent with the spirit of this invention. Such oligonucleotides are best described as moieties that are structurally distinguishable from yet functionally interchangeable with naturally occurring or synthetic wild type oligonucleotides. All such oligonucleotides are comprehended by this invention so long as they function effectively to mimic the structure of a desired RNA or DNA strand.
For use in antisense methodology, the phosphorothioate oligonucleotides of the invention preferably comprise from about 10 to about 30 subunits. It is more preferred that such oligonucleotides comprise from about 15 to about 25 subunits. As will be appreciated, a subunit is a base and sugar combination suitably bound to adjacent subunits through a phosphorothioate linkage. When used as "building blocks" in assembling phosphorothioate oligonucleotides, even smaller assemblies are preferred. The smallest assembly is a phosphorothioate nucleotide having S-(alkaryl or aryl) and alkyl ester groups. The smallest dinucleoside assembly is two nucleosides linked by a protected phosphorothioate linkage.
It will be recognized that phosphorothioate oligonucleotides having tens or even hundreds of individual nucleotide subunits can be prepared utilizing the processes and intermediates of this invention. Such very large phosphorothioate oligonucleotides can be assembled from smaller oligonucleotide intermediates that, in turn, would be assembled from even smaller intermediates. Thus, phosphorothioate oligonucleotides and phosphorothioate oligonucleotide intermediates of the invention contain one or more subunits.
The phosphorothioate oligonucleotides of the invention can be used in diagnostics, therapeutics and as research reagents and kits. They can be used in pharmaceutical compositions by including a suitable pharmaceutically accept
able diluent or carrier. They further can be used for treating organisms having a disease characterized by the undesired production of a protein. The organism should be contacted with a phosphorothioate oligonucleotide having a sequence that is capable of specifically hybridizing with a strand of nucleic acid coding for the undesirable protein. Treatments of this type can be practiced one a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms. Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular control is susceptible to therapeutic and/or prophylactic treatment in accordance with the invention. Seemingly diverse organisms such as bacteria, yeast, protozoa, algae, all plants and all higher animal forms, including warm-blooded animals, can be treated. Further, since each cell of multicellular eukaryotes can be treated since they include both DNA-RNA transcription and RNA-protein translation as integral parts of their cellular activity. Furthermore, many of the organelles (e . g . , mitochondria and chloroplasts) of eukaryotic cells also include transcription and translation mechanisms. Thus, single cells, cellular populations or organelles can also be included within the definition of organisms that can be treated with therapeutic or diagnostic phosphorothioate oligonucleotides. As used herein, therapeutics is meant to include the eradication of a disease state, by killing an organism or by control of erratic or harmful cellular growth or expression.
In the process illustrated in Scheme 1, thiophosphoryl chloride (PSCl3; structure 1) is treated with an alkyl alcohol such as cyanoethanol (structure 2) in the presence of a suitable HCl scavenger to yield a mixture of mono, di and tri alkylated phosphorothioate species (mixture 1; structures 3, 4 and 5). C1 to C10 alkyl alcohols are preferred. Even more preferred are alkyl alcohols comprising a substituent that can be activated to facilitate removal of the alkyl group. For example, cyanoethanol contains a cyanoethyl moiety that can be eliminated via a controlled β-elimination reaction. Other
useful alkyl alcohols include electron withdrawing groups positioned on the alkyl chain such that reaction with PSCl3 results in an acidic proton located on the carbon atom β to the phosphorus atom. Representative electron withdrawing groups include methyl groups [Daub, G.W. and van Tamelen, E.E. (1976) J. Am . Chem . Soc. 98:3526.], 2,2,2-trichloroethyl groups [Letsinger, R.L. and Lunsford, W.B. (1976) J. Am . Chem . Soc , 98:3655] and trihalomethylethyls such as trichlordimethylethyl, trichloromethylethyl, tribromodimethylethyl, tribromo- methylethyl and tribromoethyl [See, e .g. , United States patent 4,672,110]. A preferred HCl scavenger is 2,6-lutidine, which facilitates the reactivity of the alkyl alcohol with the chloro substituents of the PSCl3. Other useful HCl scavengers include diisopropylethylamine, 2-methylpyridine or other hindered tertiary amines.
Reaction of thiophosphoryl chloride with an alkyl alcohol such as cyanoethanol yields a mixture (mixture 1) of di-chloro-β-cyanoethyl phosphorothioate monoester (structure 3), chloro-di-(β-cyanoethyl) phosphorothioate diester (structure 4) and tri-β-cyanoethyl phosphorothioate triester
(structure 5). In accordance with the invention, the chloro groups of structure 3 and structure 4 are then hydrolyzed.
Also, one of the alkyl esters of structure 5 should be cleaved.
For example, cyanoethyl esters can be cleaved via a β-elimina- tion reaction to yield a further mixture (mixture 2) containingβ-cyanoethyl phosphorothioate ester (structure 6) and di(β- cyanoethyl) phosphorothioate ester (structure 7). Preferably hydrolysis and cleavage are effected concurrently by treating mixture 1 with an aqueous tertiary alkylamine. Preferred tertiary alkylamines are trialkyl amines such as triethylamine and diisopropylethyl amine. The electron withdrawing effect of the cyano group is believed to result in abstraction by the tertiary alkyl amine of a cyanoethyl proton and elimination of the cyanoethyl ester. A 1:1 (volume:volume) mixture of 0.5 M triethylamine buffer in acetonitrile is preferred.
Structures 3 and 4 can be hydrolyzed without cleavage of structure 5 by, for example, treating mixture 1 with an
amine species that does not effect β-elimination. Unreacted structure 5 then can be removed from the hydrolysis product. It will be recognized, however, that the overall yields from such a procedure likely will be low.
While not wishing to be bound by any particular theory, it is believed that hydrolysis of the chloro moieties of structures 3 and 4 is more facile than the ester β- elimination in structure 5. Thus, treatment of mixture 1 with aqueous amine results in hydrolysis of the chloro groups before ester cleavage. It also is believed that the presence of an anionic charge on a phosphorothioate ester of mixture 1 or mixture 2 inhibits subsequent β-elimination of β-cyanoethyl esters.
Accordingly, the phosphorothioate moieties that result upon β-elimination of a first cyanoethyl ester group of structures 4 or 5 or upon hydrolysis of a chloro group of structures 3 or 4 have a single anionic charge. The presence of this charge inhibits β-elimination of β-cyanoethyl ester groups. As a result, structure 5 is cleaved to form a di-(β- cyanoethyl) phosphorothioate diester (structure 6). Structure
4 is hydrolyzed to this same compound and structure 3 is hydrolyzed to a β-cyanoethyl phosphorothioate monoester (structure 7). If ester elimination is more facile than hydrolysis, elimination of a first ester moiety from structure 4 would generate an anionic charge that, in turn, would inhibit elimination of the remaining ester group to form structure 7. Hydrolysis of a first chloro group of structure 3 is expected to be even more facile than hydrolysis of the single chloro group of structure 4. This would generate an anionic structure that would prevent elimination of the ester group of structure
3 prior to hydrolysis of the second chloro group. However, if ester elimination is more facile than hydrolysis of the first chloro group, elimination of the ester group of structure 3 followed by hydrolysis would generate phosphorothoic acid or phosphorothiolic acid. As shown in the experimental examples below, such acids would be easily removed during work up of the reactions mixtures.
In accordance with the invention, mixture 2 is then reacted with an alkaryl halide or an aryl halide (structure 8) such as a benzyl, substituted benzyl, phenyl or substituted phenyl halide. This results in the formation of an S-alkaryl or S-aryl ester, i.e. an S-benzyl ester or an S-phenyl ester. Esterification of the thio moieties of structures 6 and 7 with an aryl halide yields a mixture containing S-(alkaryl or aryl)- di-(β-cyanoethyl) phosphorothioate triester (not illustrated or numbered) and S-(alkaryl or aryl) β-cyanoethyl phosphorothioate diester (structure 9). Concurrent treatment with a tertiary alkylamine results in β-elimination of one of the cyano-ethyl ester groups of the S-(alkaryl or aryl)-di-(β-cyanoethyl) phosphorothioate to provide an S-(alkaryl or aryl)-β-cyanoethyl phosphorothioate diester having structure 9. This S-(alkaryl or aryl) alkyl phosphorothioate diester salt has a single anionic charge and, thus, is inert to further β-elimination.
Structure 9 preferably is a triethyl ammonium salt, a diisopropylethyl ammonium salt, or a mixture thereof. Representative compounds having structure 9 include S-(4- chlorobenzyl)-β-cyanoethyl phosphorothioate diester salt, S-
(2,4-dichlorophenyl)-β-cyanoethyl phosphorothioate diester salt, S-(2,4-dichlorophenyl)-β-cyanoethyl phosphorothioate diester salt and S-benzyl-β-cyanoethyl phosphorothioate diester salt. S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester salt is preferred.
As shown in Scheme II, a salt having structure 9 can be used to directly phosphitylate a 3'-hydroxy nucleoside (structure 10) to produce a nucleoside S-(aryl) alkyl phosphorothioate triester (structure 11). For this phosphitylation reaction, the 5' hydroxyl group of the nucleoside is first blocked with a suitable blocking group (Y). Depending on the nucleoside, it also may be desirable to block the nucleoside on its heterocyclic base (Bx). For example, thymidine (or uracil if RNA nucleosides are utilized) need only be blocked at the 5' hydroxyl position, while cytidine and adenosine preferably also are blocked on their heterocyclic bases utilizing benzyl blocking groups. Guanosine should be blocked at the 6-keto
position of its heterocyclic base with a suitable keto blocking group including but not limited to diphenylcarbamate, isobutyryl (after first reacting with 1,2-glyoxal and including an additional isobutyryl group at the N2 position of the heterocyclic base in the manner of Matsuzaki, J., Kohno, K., Tahara, S., Sekine, M. and Hata, T. (1987) Bull . Chem . Soc. Jpn . , 60:1407), and β-eliminators such as cyanoethoxy groups. The guanosine nucleoside is then further blocked at the 5' hydroxyl. A wide variety of nucleosides having general structure 10 can be incorporated into phosphorothioate oligonucleotides utilizing the process of the invention. Suitable nucleosides are disclosed in the patents, patent applications, and/or papers noted above.
The 5' hydroxyl blocking group Y can be selected from dimethoxytrityl (DMTr), methoxytrityl (MTr), trityl (Tr), tert- butyldimethylsilyl (TBDMSi), tert-butoxydiphenylsilyl (TBODPSi), dialkylphosphite, pivalylisobutyloxycarbonyl and other known hydroxyl blocking groups. Dimethoxytrityl and tert-butoxydiphenylsilyl groups are preferred. Generally, blocking group Y is selected to be base stable and acid labile. Deblocking of such groups usually can be effected with acids such as 3% trichloroacetic acid (3% TCA) or a Lewis acid such as ZnBr2 or TiCl4. See, e . g. , Matteucci, M.D. and Caruthers, M.H. (1981) J . Am . Chem . Soc , 103:3185]
Since the nucleoside of structure 11 does not bear an anionic charge, treatment with an amine removes the remaining β-cyanoethyl ester group on the phosphorothioate moiety to yield structure 12. Treatment of structure 11 with acid removes the 5' hydroxyl blocking group and yields structure 13, i.e. a phosphorothioated nucleoside having a free 5' hydroxyl group. For example, dimethoxytrityl blocking groups can be removed with either 3% trichloroacetic acid or ZnBr2.
Compounds having structure 12 are then reacted with compounds having structure 13 as shown in Scheme III to yield dinucleotides having structure 14. Structure 14 bears blocking group Y on its 5' terminal hydroxyl and a β-cyanoethyl ester blocking group on its 3' terminal phosphorothioate. 3'-
Terminal blocking groups are represented by the symbol X in certain structures of this specification.
Reaction of structures 12 and 13 is conducted in the presence of an activating agent. Preferred activating agents are disclosed by Yau, E.K., Ma, Y.-X. and Caruthers, M.H. (1990) Tetrahedron Letters, 31:1953. A particularly preferred activating agent is triisopropylbenzenesulfonylchloride (TPSCl), which normally is used in the presence of a nucleophilic catalyst such as 1-methylimidazole.
Dinucleotide structure 14 can be deblocked at its 3' terminal phosphorothioate to yield compounds of structure 15 and at its 5' terminal hydroxyl group to yield compounds of structure 16. Reaction of dinucleotide compounds having structures 15 and 16 in the presence of the activating agent will yield tetrameric oligonucleotides having structure 17, as shown in Scheme IV. Oligonucleotides having structure 17 can then be elongated using reactions analogous to those shown in Schemes II or III to effect the addition of nucleosides, phosphorothioate nucleotides, phosphorothioate dinucleotides or phosphorothioate oligonucleotides. These reactions should involve deblocking (de-esterification) at a terminal 3' phosphorothioate and reaction in the presence of an activating agent with a further nucleoside, nucleotide or oligonucleotide having a free 5' terminal hydroxyl group.
Phosphodiester or other non-phosphorothioate nucleotides, dinucleotides or oligonucleotides can be added to the phosphorothioate oligonucleotide intermediates of this invention by reacting the non-phosphorothioate species with an activated phosphorothioate intermediate such as structure 12, structure 15, structure 17 or structure 22. To add a non- phosphorothioate species at a 3' terminus of a phosphorothioate intermediate, the non-phosphorothioate species should have a free 5' hydroxyl group that can form an ester linkage with the phosphorothioate intermediate or other like structure. To add a non-phosphorothioate species at the 5' terminus of a phosphorothioate intermediate, the non-phosphorothioate species should be added as an activated species to a phosphorothioate
intermediate such as structure 13, structure 16 or structure 20 having a free 5' hydroxyl group.
Upon synthesis of a phosphorothioate oligonucleotide having a desired antisense or other sequence, the S-alkaryl or S-aryl blocking groups on the phosphorothioate linkages are removed. Deblocking of the S-alkaryl or S-aryl group preferably is effected utilizing thiophenolate in the manner described by Brill, W. K.-D., Nielsen, J. and Caruthers, M.H. (1991) J. Am . Chem . Soc , 113:3972. Other deblocking conditions using thiophenol are described by Brill, W. K.-D., Tang, J.-T., Ma, Y.-X. and Caruthers, M.H. (1989) J. Am . Chem . Soc , 111:2321.
In the following schemes Y is a blocking group, M is a metal salt, Bx is a heterocyclic base, TPSC1 is triisopropylbenzenesulfonylchloride, Melm is methylimidazole, TCA is trichloroacetic acid, THF is tetrahydrofuran, DMTr is dimethoxytrityl and OCE is cyanoethoxy.
where X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide; Y is H, a second blocking group, a nucleoside, a nucleotide or an oligonucleotide; R is an alkaryl or aryl group; n is an integer greater than 0; and Bx is a heterocyclic base.
These procedures also can be used to prepare oligonucleotide of the structure:
where X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide; Y is H, a second blocking group, a nucleoside, a nucleotide or an oligonucleotide;
Z is X or P-S-R
O-X;
R is an aryl group; n is an integer greater than 0; and Bx is a heterocyclic base.
In each of these structures, heterocyclic base groups
Bx of individual nucleosides or nucleotides can be the same or different. Bx preferably is a purin-9-yl or pyrimidin-1-yl base, more preferably adenine, guanine, cytosine, thymine, uracil, hypoxanthine, 2-aminoadenine or 5-methylcytosine.
Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting.
EXAMPLES
Material and Methods. All reaction solvents were purified by known methods. The phrase "worked up in the usual manner" refers to washing the organic layer with saturated NaHCO3, water and saturated brine, drying it over Na2SO4, filtering and evaporating to dryness. Solvent deoxygenation was accomplished by bubbling a stream of argon through the solvent during two freeze-thaw cycles using a dry ice/2-pro- panol bath. NMR proton spectra are reported as parts per million versus internal tetramethylsilane standards. Phosphorus resonances are reported relative to phosphoric acid.
EXAMPLE 1
S-(2,4-Dichlorobenzyl)-β-cyanoethyl phosphorothioate diester salt (9).
Method A:
To a solution of 6.83 ml (7.11 g; 100 mmole) of 3-hydroxypropionitrile and 11.8 ml ( 10.7 g; 100 mmole) of 2,6-lutidine in 60 ml THF was added dropwise 5 ml (8.47 g; 50 mmole) of PSCl3. The mixture was stirred at r.t. under argon for 3 days, at which time the precipitate was filtered off and washed with THF twice. The combined filtrate was concentrated in vacuo to give a crude intermediate. This intermediate was immediately treated with 600 ml of CH3CN/0.5 M triethylammonium bicarbonate buffer (PH 7.0) (1/1; v/v) at r.t. for 1 day.
Solvent was removed in vacuo and the resulting residue was coevaporated once with H2O/Et3N (9/1; v/v), twice with dry pyridine and then further dried under high vacuum overnight. The dried intermediate was dissolved in 200 ml DMF and 34 ml (25.2 g; 195 mmole) of diisopropylethylamine. To this solution was added 20.8 ml (29.3 g; 150 mmole) of α,2,4-trichlorotoluen- e. The reaction mixture was stirred at r.t. under argon for 1½ days, at which time the precipitate was removed by filtration and the filtrate was evaporated in vacuo. The obtaining residue was dissolved in CH2Cl2 and washed with H2O once. The H2O layer was back washed once with CH2Cl2and the CH2Cl2 layers were combined, washed once with saturated NaCl, dried over Na2SO4, filtered and evaporated to give a crude syrup. This syrup was triturated with hexane (3 x 200 ml) and then purified by flash column on C-18 reverse phase silica gel (4:6 MeOH/H2O- ). Fractions which contained the desired product (checked by UV at 230 & 240 nm and 31P-NMR) were pooled and concentrated. The syrupy product (9) (9.49 g) was obtained as a 9:1 mixture of the diisopropylethyl ammonium and triethyl ammonium salt forms, respectively. (42% yield based on PSCl3) 31P-NMR (CDCl3; ppm) : 17.1. 1H-NMR (CDCl3; δ) : 7.51 (d, J=8.3 Hz, 1H, ArH), 7.35 (d, J=2.1 HZ, 1H, ArH), 7.18 (dd, J=8.3 & 2.1 Hz, 1H, ArH), 4.00 (m, 4H, SCH2 & OCH2), 3.58 (m, 1.8H, CH), 3.04 (m, 2.4H, CH2), 2.61 ( t, J=6.4 Hz, 2H, CH2CN), 1.40 (m, 14.4H, CH3) .
Method B:
The procedure as described in method A was followed except that Et3N was used instead of diisopropylethyl amine in the last alkylation step to provide 77.8 g of (9) from 0.5 mole of PSCl3. (36%) 31P-NMR showed the product in this preparation contained 2% phosphorus impurity and 1H-NMR showed it contained some aromatic impurity. However, these impurities did not interfere with the following phosphorylation reaction.
EXAMPLE 2
5'-O-Dimethoxytrityl-deoxythymidine-3'-[S-(2,4-di- chlorobenzyl)-β-cyanoethyl] phosphorothioate (11a).
Method A:
To a solution of 1.09 g (2 mmole) of 5'-O-dimethoxy- trityldeoxythymidine and 1.23 g (2.72 mmole) of (9) in 20 ml THF was added simultaneously 2.09 g (3.45 eq) of TPSCI and 0.92 ml (0.577 eq) of 1-methylimidazole. The reaction mixture was stirred at r.t. under argon for 2 h, at which time the gummy precipitate was filtered off, the filtrate was evaporated to half of its original volume and then precipitated into hexane. The collected precipitate was purified by flash column chroma- tography on silica gel (95:5:0.8 CH2Cl2/MeOH/pyridine) to give 1.48 g of (11a) as a foam. (87%) 31P-NMR (CDCl3, ppm) : 28.0. 1H-NMR (CDCl3; δ) 9.10 (br s, 1H, NH), 7.53 (br s, 1H, H6), 7.40-6.80 (m, 16H, ArH), 6.42 (m, 1H, H1 ' ) , 5.20 (m, 1H, H3'), 4.15 (m, 5H, H4', OCH2 & SCH2) , 3.79 (s, 6H, OCH3), 3.40 (m, 2H, H5'), 2.72-2.30 (m, 4H, CH2CN & H2'), 1.93 (s, 3H, CH3).
Method B:
To compare the above product of Method A prepared by the methods of the invention to a product prepared as per a further procedure a solution of 2.0 g (2.69 mmole) of commercial 5'-O-dimethoxytrityl-deoxythymidine 3'-phosphoramidite in 10 ml CH3CN was added to 1.03 ml (1.56 g; 3 eq) of 2,4-di- chlorobenzylmercaptane and a solution of 0.473 g (2.5 eq) of tetrazole in 15 ml CH3CN. The reaction mixture was stirred at r.t under argon for lh, at which time about 27 ml of 0.1 M I2 in THF/pyridine/H2O (7/2/1; v/v) was added dropwise to this mixture. The resulting solution was stirred at r.t. for lh. Solvent was removed in vacuo and the residue was worked up in the usual manner in EtOAc. The crude product was purified by flash column chromatography on silica gel (9:1 CH2Cl2/EtOAc → 1:1 CH2Cl2/EtOAc→ 4:6:0.5 CH2Cl2/EtOAc/MeOH; all solvent systems contained 1% pyridine) to give 1.76 g of (lla) with a small amount of impurity. (77%).
EXAMPLE 3
N6-Benzoyl-5'-O-dimethoxytrityl-deoxycytidine-3'-[S(- 2,4-dichlorobenzyl)-β-cyanoethyl] phosphorothioate (11b).
Crude (11b) was obtained from 21.8 mmole of N6-benzoyl-5'-O-di- methoxytrityl-deoxycytidine by using a similar method to that described for the preparation of (11a). This crude product was purified by flash column chromatography on silica gel (50:35:1- 5:0.7 EtOAc/CH2Cl2/acetone/pyridine) to give 17.8 g of (11b) as a foam. (87%) 31P-NMR (CDCl3, ppm) : 28.1, 28.0. 1H-NMR (CDCl3; δ) : 8.75 (br s, 1H, NH), 8.13, 7.88 (2d, 2H, H6 & H5), 7.87-6.80 (m, 21H, ArH), 6.29 (m, 1H, H,'), 5.16 (m, 1H, H3'), 4.38, 4.29 (2m, 1H, H4'), 4.14 (m, 4H, OCH2 & SCH2), 3.80, 3.79 (2s, 6H, OCH3), 3.45 (m, 2H, H5'), 2.92, 2.32 (2m, 2H, H2'), 2.68 (m, 2H, CH2CN) .
EXAMPLE 4
5'-O-Dimethoxytrityl-deoxythymidine-3'-[S-(2,4-di- chlorobenzyl)] phosphorothioate triethyl ammonium salt (12a).
Crude (12a) (10.1 g; 93%) was obtained from 12 mmole of (11a) by stirring a solution of 11a in 95 ml of CH3CN/Et3N (1/1;v/v) at r.t. for 3 hr. The solvent was removed to give the crude 12a. This crude product was used directly in the subsequent coupling reaction without any further purification.
31P-NMR (CDCl3, ppm): 17.7. tø-NMR (CDCl3; δ) : 8.50 (br s, NH),
7.60 (s, H6), 7.44-6.80 (m, ArH), 6.44 (m, H,'), 5.04 (m, H3'), 4.15 (br s, H4'), 4.00, 3.94 (2s, SCH2), 3.77 (s, OCH3), 3.29
(m, H5'), 3.04 (q, Et3N), 2.60, 2.30 (2m, H2'), 1.30 (m, CH3 &
Et3N).
EXAMPLE 5
N6-Benzoyl-5'-O-dimethoxytrityl-deoxycytidine-3'-[S- (2,4-dichlorobenzyl)] phosphorothioate triethyl ammonium salt (12b).
Crude (12b) (12.01 g; > 100%) was obtained from 10.7
mmole of (11b) by using a similar method to that described for the preparation of (12a) . 31P-NMR (CDCl3, ppm) : 17.6. 1H-NMR (CDCl3; δ) : 8.61 (br s, NH) , 8.15, 7.88 (2d, H6&H5) , 7.87-6.80 (m, ArH) , 6.29 (t, H1') , 4.98 (m, H3') , 4.28 (m, H4') , 4.01, 3.95 (2S, SCH2) , 3.78, 3.77 (2s, OCH3) , 3.32 (m, H5') , 3.01 (q, Et3N), 2.25 (2m, H2') , 1.30 (t, Et3N) .
EXAMPLE 6
Deoxythymidine-3'-[S-(2,4-dichlorobenzyl)-β-cyanoethyl] phosphorothioate (13a).
Crude (13a) was obtained from a solution of 11.4 mmole of (11a) in 20 ml of 3% trichloroacetic acid in CH2Cl2 stirred for 20 mins. The mixture was diluted with CH2Cl2 and the CH2Cl2 layer worked up in the usual manner. This crude product was purified by flash column chromatography on silica gel (6:4 EtOAc/CH2Cl2 → EtOAc → 9:1 EtOAc/acetone) to give 5.11 g of (13a) as a foam (81%). 31P-NMR (CDCl3, ppm): 28.8, 28.4. 1H-NMR (CDCl3; δ): 9.0 (br s, 1H, NH), 7.46-7.23 (m, 4H, H6 & ArH), 6.14 (2t, J= 6 .4 Hz, 1H, H1'), 5.20 (m, 1H, H3'), 4.20 (m, 5H, H4', OCH2 & SCH2), 3.85 (m, 2H, H5'), 3.08 (br s, 1H, OH), 2.75 (m, 2H, CH2CN) , 2.45 (m, 2H, H2'), 1.92 (s, 3H, CH3).
EXAMPLE 7
N6-Benzoyl-deoxycytidine-3'-[S-(2,4-dichlorobenzyl)β- cyanoethyl] phosphorothioate (13b).
A solution of 9.15 g (9.72 mmole) of (11b) in 180 ml of saturated ZnBr2 solution in CH2Cl2/2-propanol (9/1; v/v) was stirred at r.t. for 30 min. The reaction mixture was diluted with CH2Cl2 (sticky and gummy precipitate formed) and saturated
NaHCO3 solution. The resulting mixture was stirred and shaken for 20 min. (colorless solid precipitate formed) The mixture was filtered and the remaining orange gummy precipitate was converted to the colorless solid precipitate by trituration with CH2Cl2/saturated NaHCO3 (1/1; v/v) several times. All of the solid precipitate was extracted several times with CH2Cl2/s- aturated NaHCO3 (1/1; v/v) until tic showed no more product in the CH2Cl2 layer. The combined CH2Cl2 layers were washed with
saturated NaHCO3 once, H2O once and saturated NaCl once. All of the aqueous wash (including saturated NaCl) was back washed with CH2Cl2 twice. The combined CH2Cl2 layers were dried over Na2SO4, filtered and evaporated to give 8.61 g of crude product. The crude product was purified by flash column chromatography on silica gel (60:25:15 EtOAc/CH2Cl2/acetone → 56:25:15:4 EtOAc/CH2Cl2/acetone/MeOH) to give 5.33 g of (13b) as a hygroscopic foam. (86%) 31P-NMR (CDCl3, ppm): 28.6, 28.3. 1H-NMR (CDCl3; 5): 8.91 (br s, 1H, NH), 8.25, 7.90 (2d, 2H, H6 & H5), 7.87-7.22 (m, 8H, ArH), 6.21 (t, J=6.4 Hz, 1H, H,'), 5.25 (m, 1H, H3'), 4.32-4.05 (m, 5H, H4', OCH2 & SCH2) , 3.94 (br S, 2H, H5'), 3.38 (br s, 1H, OH), 2.73, 2.50 (2m, 4H, CH2CN & H2').
EXAMPLE 8
Preparation of the fully protected TT dimer (14a). To a solution of 3,15 g (5.73 mmole) of (13a) and 6.69 g (7.43 mmole; 1.3 eq) of (12a) in 60 ml THF was added simultaneously 5.97 g (3.45 eq) of TPSCI and 2.62 ml (0.577 eq) of 1-methylimidazole. The reaction mixture was stirred at r.t. under argon for 2 h, at which time the solid precipitate was filtered off, the filtrate was evaporated to half of its original volume and then precipitated into hexane. The collected precipitate was purified by flash column chromatography on silica gel (5:4:1 EtOAc/CH2Cl2/acetone → 9:1 EtOAc/a- cetone→ 8:2 EtOAc/acetone; all solvent systems contained 0.5% pyridine) to give 7.28 g of (14a) as a foam. (95%) 31P-NMR (CDCl3, ppm): 28.9, 28.8, 28.6, 28.5, 28.4, 28.3. 1H-NMR (CDCl3; δ) : 8.85 (br s, 2H, NH), 7.54 (2 s, 1H, H6), 7.45-6.80 (m, 20H, H6 & ArH), 6.40, 6.15 (2m, 2H, H1' ) , 5.15 (m, 2H, H3'), 4.30-4.02 (m, 10H, H4', H5', OCH2 & SCH2), 3.78 (s, 6H, OCH3) , 3.38 (m, 2H, H5'), 2.72 (m, 2H, CH2CN) 2.55-2.18 (m, 4H, H2'), 1.88, 1.41, 1.38 (3s, 6H, CH3).
EXAMPLE 9
Preparation of the fully protected CC dimer (14b).
Crude (14b) was obtained from 5.5 mmole of (13b) and 7.15 mmole of (12b) by using a similar method to that described
for the preparation of (14a). The crude product was purified by flash column chromatography on silica gel (97:3:0.6 CH2Cl2/M- eOH/pyridine) to give 7.7 g of (14b) as a foam. (93%) 31P-NMR (CDCl3, ppm): 29.03, 28.99, 28.77, 28.66, 28.48, 28.39. 1H-NMR (CDCl3; δ ) : 8.75 (br s, 1H, NH), 8.13, 7.88 (2d, 2H, H6 & H5), 7.87-6.80 (m, 21H, ArH), 6.29 (m, 1H, H1'), 5.16 (m, 1H, H3'), 4.38, 4.29 (2m, 1H, H4'), 4.14 (m, 4H, OCH2 & SCH2), 3.80, 3.79 (2s, 6H, OCH3), 3.45 (m, 2H, H5'), 2.92, 2.32 (2m, 2H, H2'), 2.68 (m, 2H, CH2CN). EXAMPLE 10
Preparation of the cyanoethyl-deprotected TT dimer triethyl ammonium salt (15a).
Crude (15a) (7.06 g; 97%) was obtained from 5.28 mmole of (14a) by using a similar method to that described for the preparation of (12a). 31P-NMR (CDCl3, ppm): 27.78, 27.69, 15.76. 1H-NMR (CDCl3; δ) : 8.62 (2br s, NH), 7.55,7.51, 7.47 (3 s, H6), 7.40-6.80 (m, ArH), 6.39, 6.24 (2m, H,'), 5.21, 4.80 (2m, H3'), 4.30-4.00 (m, H4' , H5', OCH2 & SCH2), 3.78 (s, OCH3), 3.37 (m, H5'), 2.91 (q, Et3N), 2.72-1.95 (m, H2'), 1.88, 1.37 (2s, CH3) , 1.24 (t, Et3N).
EXAMPLE 11
Preparation of the 5' HO-CC dimer (16a).
Crude (16b) was obtained from 4.88 mmole of (14b) by using a similar method to that described for the preparation of (13b). The crude product was purified by flash column chromatography on silica gel (97:3 CH2Cl2/MeOH) to give 5.38 g of (16b) as a foam. (91%) 31P-NMR (CDCl3, ppm): 29.15, 29.07, 28.99, 28.82, 28.64, 28.48. 1H-NMR (CDCl3; δ) : 9.01 (br s, 2H, NH), 8.37-7.20 (4m, 20H, H6, H5 & ArH), 6.18 (m, 2H, H1'), 5.30 (m, 2H, H3'), 4.43-4.12 (m, 10H, H4', H5', OCH2 & SCH2), 3.90 (br s, 2H, H5'), 2.79 (m, 2H, CH2CN) , 2.70-1.98 (m, 4H, H2').
EXAMPLE 12
Preparation of fully protected TTCC tetramer (17).
Crude (17) (7.06 g; 97%) was obtained from 3.0 mmole
of (16b) and 3.0 mmole of (15a) by using a similar method to that described for the preparation of (14a or 14b). The crude product was purified by flash column chromatography on silica gel (75:23:2:0.7 CH2Cl2/acetone/MeOH/pyridine→ 95: 5:.7 CH2Cl2/M- eOH/pyridine) to give 6.96 g of (17) as a foam. (94%) 31P-NMR (CDCl3, ppm): 29.49-27.73 (15 peaks). 1H-NMR (CDCl3; δ) : 9.95, 9.78, 9.70, 9.34 (4br s, 4H, NH), 8.02, 7.90 (2m, 6H, H6 & H5) , 7.60-6.80 (m, 35H, ArH), 6.40, 6.20 (2m, 4H, H1'), 5.20 (m, 4H, H3'), 4.47-4.04 (m, 20H, H4' , H5', OCH2 & SCH2), 3.78 (s, 6H, OCH3), 3.40 (m, 2H, H5'), 2.90-2.12 (m, 10H, CH2CN & H2'), 1.83, 1.40, 1.38 (3s, 6H, CH3) .
EXAMPLE 13
N6-Benzoyl-5'-O-tert-Butoxydiphenylsilyl-2'-Deoxy- adenosine-3'-[S-(2,4-dichorobenzyl)-β-Cyanoethyl] Phosphorothioate (18)
A stirred solution of N6-benzoyl-5'-O-tert-butoxydi- phenylsilyl-2'-deoxyadenosine (3.32 g, 5.44 mmole) and 15 mL of a 0.512 M solution of compound 9 in THF (1.40 equiv) in 55 mL of dry THF was treated with 2,4,6-triisopropylbenzenesulfonyl chloride (5.72 g, 18.89 mmole, 5.76 equiv) at rt under argon. The progress of the reaction was monitored by tic and 31P NMR which indicated that the reaction was completed at the end of 2 hr. The insoluble organic salt was filtered off through a Buchner funnel. The organic salt was rinsed twice with 40 mL of THF and the combined filtrate and washing were concentrated at reduced pressure until the whole solution turned milky. The resultant residue was added, dropwise, into 4 L hexanes to solidify the product out from the reaction mixture. The precipitate was collected and purified by flash chromatography eluting with CH2Cl2/MeOH/pyridine (98:2:0.5) to give 2.91 g (58%) of compound 18 as a white foam. 31P NMR (CDCl3, 81 MHz) δ 28.1 and 27.9 ppm (ratio 45:55); 1H NMR (CDCl3, 400 MHz) δ 8.15 ppm (s, H-2 of minor isomer) and 8.14 ppm (s, H-2 of major isomer).
EXAMPLE 14
N6-Benzoyl-5'-O-tert-Butoxydiphenylsilyl-2'-Deoxy- adenosine-3'-S-(2,4-dichlorobenzyl) Phosphorothioate (19)
Crude compound 19 will be obtained from compound 18 by using a similar method to that described for the preparation of (12a).
EXAMPLE 15
Preparation of DMTr deprotected 5' HO-TTCC tetramer (20).
The DMT protecting group of compound 17 will be removed to yield crude compound 20 by using a similar method to that described for the preparation of (13a).
EXAMPLE 16
Preparation of the fully protected ATTCC pentamer (21).
Crude compound (19) and compound (20) will be reacted by using a similar method to that described for the preparation of (14a or 14b). The crude product will be purified by flash column chromatography on silica gel (75:23:2:0.7 CH2Cl2/aceton- e/MeOH/pyridine→ 95:5:.7 CH2Cl2/MeOH/pyridine) to give (21) as a foam.
EXAMPLE 17
Preparation of cyanoethyl deprotected DMTr-ATTCC tetramer (22).
The β-cyanoethyl protecting group of compound 21 will be removed to give crude compound 22 from compound 21 by using a similar method to that described for the preparation of (12a).
EXAMPLE 18
Preparation of protected ATTCCG hexamer (23).
Crude (23) will be obtained from (22) and 3'-O-trityl- 2'-deoxyguanosine by using a similar method to that described
for the preparation of (14a or 14b). The crude product will be purified by flash column chromatography on silica gel (75:23:2- :0.7 CH2Cl2/acetone/MeOH/pyridine→ 95:5:.7 CH2Cl2/MeOH/pyridine) to give (23) as a foam. EXAMPLE 19
Preparation of fully deprotected ATTCCG Phosphorothioate hexamer (24).
Compound (23) will be DMTr deprotected utilizing a similar method to that described for the for the preparation of (13a). The crude product from that reaction is then further deprotected by the removal of the S-(2,4-dichlorobenzyl) groups by treatment with thiophenolate in the manner as described by Brill, W. K.-D., Nielsen, J. and Caruthers, M.H. (1991) J. Am . Chem . Soc , 113:3972. Other Synthetic Methods
EXAMPLE 20
5'-O-Dimethoxytrityl-deoxythymidine-3'(-o-chloro- phenyl-β-cyanoethyl) phosphorothioate (25).
To a solution of 1.99 g (2.67 mmole) of commercial 5'-O-dimethoxytrityl-deoxythymidine 3'-phosphoramidite in 10 ml dried and deoxygenated CH3CN was added 0.83 ml (1.03 g; 3 eq) of 2-chlorophenol and a solution of 0.47 g (2.5 eq) of tetrazole in 15 ml dried and deoxygenated CH3CN. The reaction mixture was stirred at r.t. under argon for 1 h, at which time a solution of S8 (1 g in 9 ml of CS2 and 9 ml of pyridine) was added until the yellow color persisted. The mixture was then stirred at r.t. for 1-2 h. An aliquot of this mixture was withdrawn and analyzed by 31P-NMR, which indicated that the sulfurization was completed. The reaction mixture was diluted with EtOAc and the sulfur precipitate was removed by filtration. The filtrate was concentrated and the resulting residue was worked up in EtOAc in the usual manner. The crude product was purified by flash column chromatography on silica gel (first 80:20:0.8 CH2Cl2/EtOAc/pyridine and then 50:50:0.8 CH2Cl2/EtOAc/pyridine) to give 1.98 g of (25) as a foam. (92%)
31P-NMR (CDCl3; ppm) : 62.9, 62.5. Η-NMR (CDCl3; δ) : 9.08, 9.05 (2s, 1H, NH) , 7.61, 7.59 (2s, 1H, H6) , 7.44-6.80 (m, 17H, ArH) , 6.50 (m, 1H, H1' ) , 5.50 (m, 1H, H3'), 4.39 (m, 3H, H4' & OCH2) , 3.79 (s, 6H, OMe), 3.45 (m, 2H, H5'), 2.75 (2t, 2H, CH2CN) , 2.66, 2.44 (2m, 2H, H2') , 1.45, 1.43 (2s, 3H, CH3) .
EXAMPLE 21
Deoxythymidine-3'(-o-chlorophenyl-β-cyanoethyl) phosphorothioate (26).
A solution of 1.10 g (1.37 mmole) of (25) in 20 ml of 3% trichloroacetic acid in CH2Cl2 was stirred at r.t. for 30 min. The mixture was diluted with CH2Cl2and the CH2Cl2 layer was worked up in the usual manner. The crude product was purified by flash column chromatography on silica gel (first 1:1
CH2Cl2/EtOAc and then EtOAc) to give 579 mg pure (26) as a colorless foam. (84%) 31P-NMR (CDCl3; ppm): 61.3, 61.0. 1H -NMR
(CDCl3; δ) : 8.80 (br s, 1H, NH), 7.45, 7.44 (2s, 1H, H6),
7.37-7.16 (m, 4H, ArH), 6.23 (t, 1H, H1'), 5.41 (m, 1H, H3'),
4.45 (m, 2H, OCH2), 4.33 (m, 1H, H4'), 3.93 (m, 2H, H5'), 2.83
(t, 2H, CH2CN), 2.78 (br s, 1H, OH), 2.58 (m, 2H, H2'), 1.92 (s, 3H, CH3).
EXAMPLE 22
5'-O-Dimethoxytrityl-deoxythymidine-3'(-o-chloro- phenyl) phosphorothioate triethyl ammonium salt (27). A solution of 900 mg (1.12 mmole) of (25) in 9.5 ml of CH3CN/Et3N (1/1;v/v) was stirred at r.t. for 3 h. Solvent was removed in vacuo to give the crude (27) in a quantitative yield. This crude product was used directly in the coupling reaction without any further purification. 31P-NMR (CDCl3; ppm): 53.3, 52.5. 1H-NMR (CDCl3; δ) : 8.52 (br s, NH), 7.65, 7.60 (2s, H6), 7.42-6.76 (m, ArH), 6.48 (m, H1'), 5.60, 5.50 (2m, H3'), 4.41 (m, H4'), 3.78 (s, OCH3), 3.44 (m, H5'), 3.05 (q, Et3N), 2.71, 2.42 (2m, H2'), 1.32 (m, CH3 & Et3N) .
EXAMPLE 23
Preparation of the fully protected TT dimer (28).
To a solution of 251 mg (0.5 mmole) of (26) and 491 mg (0.757 mmole: 1.1 eq) of (27) in 9.3 ml THF was added simultaneously 523 mg (3.45 eq) of triisopropylbenzenesulfonyl chloride (TPSCI) and 0.23 ml (0.237 g; 5.77 eq) of 1-methylimidazole. The mixture was stirred at r.t. under argon and the progress of the reaction was monitored by 31P-NMR and tic. After 2½ h, the reaction was quenched with 5 ml of pyridine/H2O (2/1; v/v) and then worked up in the usual manner in CH2Cl2. The crude product was purified by flash column chromatography on silica gel (95:5:0.8 CH2Cl2/MeOH/pyridine) to give 330 mg of pure (28) as a colorless foam. (53%) 31P-NMR (CDCl3; ppm): 62.0, 61.8, 61.7, 61.6, 61.3, 61.2. 1H-NMR (CDCl3; δ) : 8.85-8.60 (6s, 2H, NH), 7.57 (s, 1H, H6), 7.48-6.81 (m, 22H, H6 & ArH), 6.39 (m, 2H, H1'), 5.50 (m, 2H, H3'), 4.56-4.20 (m, 6H, H4', H5' & OCH2), 3.78 (s, 6H, OCH3), 3.21 (m, 2H, H5'), 2.82 (m, 2H, CH2CN), 2.75-2.28 (m, 4H, H2'), 1.81, 1.42, 1.41 (3s, 6H, CH3). Those skilled in the art will appreciate that numerous changes and modifications can be made to the preferred embodiments of the invention and that such changes and modifications can be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.
Claims
1. A process for preparing a phosphorothioate oligonucleotide, comprising the steps of:
(a) reacting PSCl3 with an alkaryl halide or an aryl halide to form a first reaction intermediate;
(b) reacting said first reaction intermediate with a nucleoside having a 3'-hydroxyl group, a nucleotide having a 3'-hydroxyl moiety, or a oligonucleotide having a 3'-hydroxyl moiety to form a second reaction intermediate selected from a nucleoside 3'-S-aryl phosphorothioate, a nucleotide 3'-S- (alkaryl or aryl) phosphorothioate or an oligonucleotide 3'-S- (alkaryl or aryl) phosphorothioate; and
(c) reacting said second reaction intermediate with a nucleoside having a 5'-hydroxyl moiety, a nucleotide having a 5'-hydroxyl moiety or an oligonucleotide having a 5'-hydroxyl moiety in the presence of an activating agent to form an ester linkage between an S-(alkaryl or aryl) phosphorothioate moiety of said second reaction intermediate and said 5 '-hydroxyl moiety.
2. The process of claim 1 further including:
hydrolyzing said PSCl3 prior to reacting said PSCl3 with said alkaryl or aryl halide; and
reacting said hydrolyzed PSCl3 with said alkaryl or aryl halide.
3. The process of claim 1 further including:
reacting said PSCl3 with an alkyl alcohol to form an alkoxy intermediate prior to reacting said PSCl3 with said alkaryl or aryl halide;
hydrolyzing said alkoxy intermediate; and
reacting said hydrolyzed alkoxy intermediate with said alkaryl or aryl halide.
4. The process of claim 1 further including reacting the product of step (c) with a nucleoside 3'-S-(alkaryl or aryl) phosphorothioate, a nucleotide 3'-S-(alkaryl or aryl) phosphorothioate or a first oligonucleotide 3'-S-(alkaryl or aryl) phosphorothioate.
5. The process of claim 3 further including reacting the product of step (c) with a nucleoside 3'-S-(alkaryl or aryl) phosphorothioate, a nucleotide 3'-S-(alkaryl or aryl) phosphorothioate or an oligonucleotide 3'-S-(alkaryl or aryl) phosphorothioate.
6. The process of claim 1 including selecting a chloro-substituted benzyl halide as said alkaryl or aryl halide.
7. The process of claim 1 including selecting a dichlorobenzyl halide as said alkaryl or aryl halide.
8. The process of claim 1 including selecting α,2,4- trichlorotoluene as said alkaryl or aryl halide.
9. The process of claim 1 including selecting triisopropylbenzenesulfonylchloride as said activating agent.
10. The process of claim 9 further including adding a nucleophilic catalyst to said activating agent.
11. The process of claim 10 including selecting 1- methylimidazole as said nucleophilic catalyst.
12. The process of claim 3 including selecting β- cyanoethanol as said alkyl alcohol.
13. The process of claim 1 further including cleaving an S-(alkaryl or aryl) bond of the product of step (c) to form a phosphorothioate diester linkage.
14. A process for preparing phosphorothioate oligonucleotides, comprising the steps of:
(a) reacting PSCl3 with an alkyl alcohol in the presence of base to form an alkoxy intermediate;
(b) hydrolyzing said alkoxy intermediate;
(c) reacting said hydrolyzed alkoxy intermediate with an alkaryl halide or an aryl halide to form a first reaction intermediate;
(d) reacting said first reaction intermediate with a nucleoside having a 3'-hydroxyl moiety, a nucleotide having a 3'-hydroxyl moiety, or an oligonucleotide having a 3'- hydroxyl moiety to a second reaction intermediate selected from a nucleoside 3'-S-(alkaryl or aryl) alkyl phosphorothioate, a nucleotide 3'-S-(alkaryl or aryl) alkyl phosphorothioate or an oligonucleotide 3'-S-(alkaryl or aryl) alkyl phosphorothioate; and
(e) reacting said second reaction intermediate with a nucleoside having a 5'-hydroxyl moiety, a nucleotide having a 5'-hydroxyl moiety or an oligonucleotide having a 5'-hydroxyl moiety in the presence of an activating agent to form an ester linkage between an S-(alkaryl or aryl) alkyl phosphorothioate moiety of said second reaction intermediate and said 5'- hydroxyl moiety.
15. The process of claim 14 including selecting α,2,4-trichlorotoluene as said alkaryl or aryl halide.
16. The process of claim 14 including selecting triisopropylbenzenesulfonylchloride as said activating agent.
17. The process of claim 16 further including adding a nucleophilic catalyst to said activating agent.
18. The process of claim 17 including selecting 1- methylimidazole as said nucleophilic catalyst.
19. The process of claim 14 including selecting β- cyanoethanol as said alkyl alcohol.
20. The process of claim 14 further including cleaving an S-(alkaryl or aryl) bond of the product of step (e) to form a phosphorothioate diester linkage.
21. A process for preparing a phosphorothioate internucleoside linkage, comprising the steps of:
reacting 5'-blocked nucleosides with an S-(alkaryl or aryl) alkyl phosphorothioate diester salt to form phosphitylated nucleosides;
removing a 5'-blocking group from one of said phosphitylated nucleosides;
dealkylating a further one of said phosphitylated nucleosides; and
reacting said dealkylated phosphitylated nucleoside with said deblocked phosphitylated nucleoside to form a dinucleoside having an S-(alkaryl or aryl) phosphorothioate internucleoside linkage.
22. The process of claim 21 further including cleaving an S-(alkaryl or aryl) bond of said S-(alkaryl or aryl) phosphorothioate internucleoside linkage to form a dinucleoside having a phosphorothioate internucleoside linkage.
23. The process of claim 21 including selecting 2,4- dichlorobenzyl as the alkaryl or aryl moiety of said S-(alkaryl or aryl) alkyl phosphorothioate diester salt.
24. The process of claim 21 including selecting β- cyanoethyl as the alkyl moiety of S-(alkaryl or aryl) alkyl phosphorothioate diester salt.
25. The process of claim 22 further including cleaving said S-(alkaryl or aryl) bond with thiophenolate.
26. A compound of the structure:
wherein:
X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide;
Y is H, a second blocking group, a nucleoside, a nucleotide or an oligonucleotide;
R is an alkaryl or aryl group;
n is an integer greater than 0; and
Bx is a heterocyclic base.
27. The compound of claim 26 wherein X is H or said first blocking group, and Y is H or said second blocking group.
28. The compound of claim 26 wherein X is H and Y is said second blocking group.
29. The compound of claim 26 wherein Y is H and X is said first blocking group.
30. The compound of claim 26 wherein R is benzyl, substituted benzyl, phenyl or substituted phenyl.
31. The compound of claim 26 wherein R is halogen- substituted benzyl.
32. The compound of claim 31 wherein R is mono- chlorobenzyl or dichlorobenzyl.
33. The compound of claim 32 wherein R is 2,4- dichlorobenzyl.
34. The compound of claim 26 wherein said second blocking group is trityl, methoxytrityl, dimeth oxrytrityl, tert- butyldimethylsilyl, tert-butoxydiphenylsilyl, alkylphosphite or pivalylisobutyloxycarbonyl.
35. The compound of claim 26 wherein said first blocking group is cyanoethyl.
36. A compound of the structure:
wherein:
X is H, a first blocking group, a nucleoside, a nucleotide or an oligonucleotide;
Y is H, a second blocking group, a nucleoside, a nucleotide or an oligonucleotide;
Z is X or P-S-R
O-X;
R is an alkaryl or aryl group;
n is an integer greater than 0; and
Bx is a heterocyclic base.
37. The compound of claim 36 wherein X is H or said first blocking group, and Y is H or said second blocking group.
38. The compound of claim 36 wherein:
Z is X;
X is H or said first blocking group; and
Y is H or said second blocking group.
39. The compound of claim 36 wherein Y is H and Z is
H.
40. The compound of claim 36 wherein R is benzyl, substituted benzyl, phenyl or substituted phenyl.
41. The compound of claim 36 wherein R is halogen substituted benzyl.
42. The compound of claim 41 wherein R is mono- chlorobenzyl or dichlorobenzyl.
43. The compound of claim 42 wherein R is 2,4- dichlorobenzyl.
44. The compound of claim 36 wherein said second blocking group is dimethoxytrityl or tert-butoxydiphenylsilyl.
45. The compound of claim 36 wherein said first blocking group is cyanoethyl.
46. The compound S-(2,4-Dichlorobenzyl)-β-cyanoethyl phosphorothioate diester or a salt thereof.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/818,928 US5210264A (en) | 1992-01-10 | 1992-01-10 | S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester |
PCT/US1993/001574 WO1994019363A1 (en) | 1992-01-10 | 1993-02-22 | Process for preparing phosphorothioate oligonucleotides |
AU37755/93A AU3775593A (en) | 1992-01-10 | 1993-02-22 | Process for preparing phosphorothioate oligonucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/818,928 US5210264A (en) | 1992-01-10 | 1992-01-10 | S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester |
PCT/US1993/001574 WO1994019363A1 (en) | 1992-01-10 | 1993-02-22 | Process for preparing phosphorothioate oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994019363A1 true WO1994019363A1 (en) | 1994-09-01 |
Family
ID=26786405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/001574 WO1994019363A1 (en) | 1992-01-10 | 1993-02-22 | Process for preparing phosphorothioate oligonucleotides |
Country Status (2)
Country | Link |
---|---|
US (1) | US5210264A (en) |
WO (1) | WO1994019363A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996027681A1 (en) * | 1995-03-03 | 1996-09-12 | Imperial Cancer Research Technology Limited | Method of nucleic acid analysis |
JP2008138005A (en) * | 1995-06-09 | 2008-06-19 | Regents Of The Univ Of Colorado | Novel protecting groups and use thereof in an improved process for oligonucleotide synthesis |
JP2013531665A (en) * | 2010-06-30 | 2013-08-08 | ギリンダス・アメリカ・インコーポレイテッド | Novel method using N-thio compounds for oligonucleotide synthesis |
WO2019055951A1 (en) * | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
IL102183A (en) * | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
FR2705099B1 (en) * | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Phosphorothioate triester oligonucleotides and process for their preparation. |
US5955591A (en) * | 1993-05-12 | 1999-09-21 | Imbach; Jean-Louis | Phosphotriester oligonucleotides, amidites and method of preparation |
US6828427B1 (en) | 1994-01-11 | 2004-12-07 | Isis Pharmaceuticals, Inc. | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same |
US5886177A (en) * | 1994-01-11 | 1999-03-23 | Isis Pharmaceuticals, Inc. | Phosphate linked oligomers |
US6184389B1 (en) | 1994-01-11 | 2001-02-06 | Isis Pharmaceuticals, Inc. | Combinatorial libraries having aminodiol monomer subunits |
US6448373B1 (en) * | 1994-01-11 | 2002-09-10 | Isis Pharmaceuticals, Inc. | Phosphate linked oligomers formed of monomeric diols and processes for preparing same |
US5519134A (en) * | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5554746A (en) * | 1994-05-16 | 1996-09-10 | Isis Pharmaceuticals, Inc. | Lactam nucleic acids |
US5510476A (en) * | 1994-07-07 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Carbocation scavenging during oligonucleotide synthesis |
US6558633B1 (en) * | 1994-09-21 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Chemical reaction apparatus and methods |
US6166197A (en) * | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
US6222025B1 (en) * | 1995-03-06 | 2001-04-24 | Isis Pharmaceuticals, Inc. | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
US5705621A (en) * | 1995-11-17 | 1998-01-06 | Isis Pharmaceuticals, Inc. | Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same |
US6639062B2 (en) | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6020475A (en) * | 1998-02-10 | 2000-02-01 | Isis Pharmeuticals, Inc. | Process for the synthesis of oligomeric compounds |
US7273933B1 (en) * | 1998-02-26 | 2007-09-25 | Isis Pharmaceuticals, Inc. | Methods for synthesis of oligonucleotides |
US6531590B1 (en) | 1998-04-24 | 2003-03-11 | Isis Pharmaceuticals, Inc. | Processes for the synthesis of oligonucleotide compounds |
AU4434299A (en) | 1998-06-11 | 1999-12-30 | Isis Pharmaceuticals, Inc. | Synthetic methods and intermediates for triester oligonucleotides |
US6326478B1 (en) | 1998-07-08 | 2001-12-04 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
US6175004B1 (en) | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
US6069243A (en) * | 1998-10-06 | 2000-05-30 | Isis Pharmaceuticals, Inc. | Process for oligonucleotide synthesis |
US6492111B1 (en) | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
US6465628B1 (en) * | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
US6486313B1 (en) | 1999-02-18 | 2002-11-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides having alkylphosphonate linkages and methods for their preparation |
US6121437A (en) | 1999-03-16 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Phosphate and thiophosphate protecting groups |
US20040082774A1 (en) * | 1999-03-16 | 2004-04-29 | Guzaev Andrei P. | Novel phosphate and thiophosphate protecting groups |
US6399765B1 (en) * | 1999-03-17 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Methods for removing dimethoxytrityl groups from oligonucleotides |
US6093807A (en) * | 1999-03-19 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Sugar-modified 7-deaza-7-substituted oligonucleotides |
US6593466B1 (en) | 1999-07-07 | 2003-07-15 | Isis Pharmaceuticals, Inc. | Guanidinium functionalized nucleotides and precursors thereof |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
EP1176151B1 (en) * | 2000-07-28 | 2014-08-20 | Agilent Technologies, Inc. | Synthesis of polynucleotides using combined oxidation/deprotection chemistry |
US6825338B2 (en) | 2001-03-30 | 2004-11-30 | Isis Pharmaceuticals, Inc. | Labeled oligonucleotides, methods for making same, and compounds useful therefor |
US6632938B2 (en) | 2001-06-07 | 2003-10-14 | Isis Pharmaceuticals, Inc. | Processes of purifying oligonucleotides |
US20030190626A1 (en) * | 2002-04-09 | 2003-10-09 | Vasulinga Ravikumar | Phosphorothioate monoester modified oligomers |
US7057062B2 (en) * | 2002-04-11 | 2006-06-06 | Isis Pharmaceuticals, Inc. | Process for manufacturing purified phosphorodiamidite |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212295A (en) * | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4393010A (en) * | 1979-12-26 | 1983-07-12 | Genentech, Inc. | Nucleosidic phosphorylating agent and methods |
US4517338A (en) * | 1983-06-20 | 1985-05-14 | Chiron Corporation | Multiple reactor system and method for polynucleotide synthesis |
US4672110A (en) * | 1983-11-29 | 1987-06-09 | Northwestern University | Method of deprotecting polynucleotide trimethylethyl phosphotriesters |
ATE271064T1 (en) * | 1990-01-11 | 2004-07-15 | Isis Pharmaceuticals Inc | OLIGONUCLEOTIDE DERIVATIVES FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION |
-
1992
- 1992-01-10 US US07/818,928 patent/US5210264A/en not_active Expired - Lifetime
-
1993
- 1993-02-22 WO PCT/US1993/001574 patent/WO1994019363A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212295A (en) * | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
Non-Patent Citations (8)
Title |
---|
ANNUAL REVIEWS OF BIOCHEMISTRY, Volume 54, issued 1985, ECKSTEIN, F., "Nucleoside Phosphorothioates", pages 367-402. * |
BIOCHEMISTRY, Volume 23, issued 1984, CONNOLLY et al., "Synthesis and Characterization of an Octanucleotide Containing the EcoRI Recognition Sequence with a Phosphorothioate Group at the Cleavage Site", pages 3443-3453. * |
J. AM. CHEM. SOC., Volume 111, issued 1989, BRILL et al., "Synthesis of Oligodeoxynucleoside Phosphorodithioates via Thioamidites", pages 2321-2322. * |
J. AM. CHEM. SOC., Volume 113, issued 1991, BRILL et al., "Synthesis of Deoxydinucleoside Phosphorodithioates", pages 3972-3980. * |
JOURNAL OF ORGANIC CHEMISTRY, Vol. 49, No. 13, issued 1984, NELSON et al., "Synthesis of P-Thioadenylyl-(2'-5')-Adenosine and P-Thioadenylyl-(2'-5')-P-Thioadenylyl-(2'-5')-Adenosine", pages 2314-2317. * |
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, Vol. 106, issued 1984, STEC et al., "Automated Solid-Phase Synthesis, Separation, Stereochemistry of Phosphorothioate Analogues of Oligodeoxyribonucleotides", pages 6077-6079. * |
SULFUR REPORTS, Volume 11, Number 1, issued 1991, DAHL, OTTO, "Preparation of Nucleoside Phosphoro-Thioates and Phosphorodithioates and Related Compounds", pages 167-192. * |
TETRAHEDRON LETTERS, Volume 31, No. 14, issued 1990, YAU et al., "Synthesis of Dinucleoside and Dinucleotide Phosphorodithioates via a Phosphotriester Approach", pages 1953-1956. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996027681A1 (en) * | 1995-03-03 | 1996-09-12 | Imperial Cancer Research Technology Limited | Method of nucleic acid analysis |
US6268129B1 (en) | 1995-03-03 | 2001-07-31 | Imperial Cancer Research Technology Limited | Method of nucleic acid analysis |
EP1498497A2 (en) * | 1995-03-03 | 2005-01-19 | Cancer Research Technology Limited | Method of nucleic acid analysis by mass spectrometry |
EP1498497A3 (en) * | 1995-03-03 | 2005-03-02 | Cancer Research Technology Limited | Method of nucleic acid analysis by mass spectrometry |
JP2008138005A (en) * | 1995-06-09 | 2008-06-19 | Regents Of The Univ Of Colorado | Novel protecting groups and use thereof in an improved process for oligonucleotide synthesis |
JP2013531665A (en) * | 2010-06-30 | 2013-08-08 | ギリンダス・アメリカ・インコーポレイテッド | Novel method using N-thio compounds for oligonucleotide synthesis |
US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
WO2019055951A1 (en) * | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
US11608355B2 (en) | 2017-09-18 | 2023-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
Also Published As
Publication number | Publication date |
---|---|
US5210264A (en) | 1993-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5644048A (en) | Process for preparing phosphorothioate oligonucleotides | |
US5210264A (en) | S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester | |
US5602244A (en) | Polynucleotide phosphorodithioate compounds | |
US5750666A (en) | Polynucleotide phosphorodithioate compounds | |
US5453496A (en) | Polynucleotide phosphorodithioate | |
US5218103A (en) | Nucleoside thiophosphoramidites | |
US5625050A (en) | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics | |
US5512668A (en) | Solid phase oligonucleotide synthesis using phospholane intermediates | |
US6051699A (en) | Process for the synthesis of oligomeric compounds | |
US5218088A (en) | Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates | |
US5510476A (en) | Carbocation scavenging during oligonucleotide synthesis | |
AU626305B2 (en) | Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and processes | |
MXPA96004355A (en) | Oligonucleotides and used modified intermediaries in nucleic acids therapeuti | |
EP0948514B1 (en) | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | |
WO1991004983A1 (en) | Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and processes | |
JPH09503494A (en) | Building blocks with carbamate internucleoside linkages and novel oligonucleotides derived therefrom | |
EP0983233B1 (en) | Reagent useful for synthesizing sulfurized oligonucleotide analogs | |
WO1990012022A1 (en) | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections | |
Schirmeister et al. | Nucleotides Part XL. Synthesis and Characterization of Modified 2′–5′ Adenylate Trimers–Potential Antiviral Agents | |
EP0064796A2 (en) | Phosphorylating agent and process for the phosphorylation of organic hydroxyl compounds | |
EP0828749B1 (en) | Methods for the synthesis of organophosphorus derivatives | |
CA2036287A1 (en) | Polynucleotide phosphorodithioate as therapeutic agents for retroviral infections | |
US6458941B1 (en) | Compounds for the synthesis of nucleotide or oligonucleotide phosphoramidites | |
IL110600A (en) | Nucleoside and polynucleotide phosphorodithioate compounds and their production | |
JPH10204097A (en) | H-phosphonate oligonucleotide derivative and production of the derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL RO RU SD SK UA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |